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Abstract
The initiation of adaptive immune responses to protein antigens has to be preceded by their
uptake by antigen presenting cells and intracellular proteolytic processing. Paradoxically,
endocytic receptors involved in antigen uptake do not bind the majority of proteins, which
may be the main reason why purified proteins stimulate at most weak immune responses. A
shared feature of different types of adjuvants, capable of boosting immunogenicity of protein
vaccines, is their ability to induce acute inflammation, characterized by early influx of activat-
ed neutrophils. Neutrophils are also rapidly recruited to sites of tissue injury or infection.
These cells are the source of potent oxidants, including hypochlorous acid (HOCl), causing
oxidation of proteins present in inflammatory foci. We demonstrate that oxidation of proteins
by endogenous, neutrophils-derived HOCl increases their immunogenicity. Upon oxidation,
different, randomly chosen simple proteins (yeast alcohol dehydrogenase, human and bo-
vine serum albumin) and glycoproteins (human apo-transferrin, ovalbumin) gain the ability to
bind with high affinity to several endocytic receptors on antigen presenting cells, which
seems to be the major mechanism of their increased immunogenicity. The mannose recep-
tor (CD206), scavenger receptors A (CD204) and CD36 were responsible for the uptake and
presentation of HOCl-modified proteins by murine dendritic cells and macrophages. Other
scavenger receptors, SREC-I and LOX-1, as well as RAGE were also able to bind HOCl-
modified proteins, but they did not contribute significantly to these ligands uptake by dendrit-
ic cells because they were either not expressed or exhibited preference for more heavily oxi-
dised proteins. Our results indicate that oxidation by neutrophils-derived HOCl may be a
physiological mechanism of conferring immunogenicity on proteins which in their native
forms do not bind to endocytic receptors. This mechanismmight enable the immune system
to detect infections caused by pathogens not recognized by pattern recognition receptors.
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Introduction
Adaptive immune responses are mainly directed against foreign (non-self) proteins. However,
Th lymphocytes, which are responsible for the initiation and orchestration of immune responses,
are not able to directly recognize native proteins, but require them being presented as complexes
of short protein fragments (epitopes) with MHC class II molecules (MHC-II) on surfaces of anti-
gen presenting cells (APC). Consequently, in order to induce immune responses, protein anti-
gens have to be first taken up by APC and subjected to intracellular proteolytic processing. Two
major mechanisms of antigen uptake by APC have been described: receptor-mediated endocyto-
sis and non-specific fluid-phase macropinocytosis [1]. Nevertheless, the observation that pinocy-
tosed antigens need to be present at even more than a thousand-times higher concentrations
than antigens undergoing receptor-mediated endocytosis in order to induce an equivalent im-
mune response [2–4], questions physiological significance of the latter mechanism in vivo. More-
over, as a result of maturation, dendritic cells (DC) which are the most proficient type of APC,
shut downmacropinocytosis, but they continue to capture, process, and present antigens inter-
nalised via endocytic receptors [5]. Paradoxically, although protein fragments are the only type
of antigens presented in the context of both class I and II MHCmolecules, the major endocytic
receptors of APC, mediating antigen uptake in non-immune hosts: scavenger receptors (SR) and
C-type lectins, do not bind the majority of proteins. This seems to be an important reason why
purified proteins are at most weakly immunogenic. However, it is possible to boost immunoge-
nicity of protein vaccines by co-administration of the so-called adjuvants. A shared feature of dif-
ferent types of adjuvants, applied in human and experimental animal vaccines, is their ability to
induce acute inflammatory responses, characterized by early appearance of activated neutrophils
and monocytes at the site of injection [6–8]. As a part of their microbicidal activity, these cells
produce large quantities of reactive oxygen species in the process called respiratory burst. In this
process, a multicomponent, membrane-anchored enzyme NADPH oxidase catalyses reduction
of molecular oxygen with an electron derived from NADPH to form superoxide anion (O2
-). Su-
peroxide anion may then undergo conversion, either spontaneous or catalysed by superoxide dis-
mutase (SOD), into hydrogen peroxide. The enzyme myeloperoxidase (MPO), being the most
abundant protein of neutrophils, present in their azurophilic granules, but also expressed by
monocytes utilizes H2O2 and chloride anions as substrates to synthesize a very potent oxidant—
hypochlorous acid (HOCl). HOCl not only contributes significantly to microbicidal activity of
neutrophils [9], but also causes indiscriminative oxidation of both host- and, if present, patho-
gen-derived proteins [10]. It has been demonstrated previously that, in comparison to unmodi-
fied ovalbumin (OVA), OVA treated with reagent HOCl (OVA-Cl) exhibits strongly enhanced
immunogenicity [11,12]. Both increased susceptibility to digestion by proteases involved in anti-
gen processing and enhanced uptake by APC were suggested as being responsible for increased
immunogenicity of OVA-Cl. However, receptors mediating this increased uptake were not iden-
tified. It is also not known whether modification of other proteins increases their immunogenici-
ty and whether endogenous HOCl, produced by activated neutrophils, is capable of producing a
similar effect. We have addressed all these questions in the presented work. Our results indicate
that modification by neutrophils-derived HOCl may be a universal, physiological mechanism of
conferring immunogenicity on proteins which in their native forms do not bind to endocytic re-
ceptors involved in the uptake of antigens.
Materials and Methods
Native proteins and their modification with HOCl
Low endotoxin ovalbumin (OVA) was obtained from Hyglos; bovine serum albumin (BSA)
from Roche Diagnostic; mouse transferrin from Rockland Immunochemicals; fatty acid and
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globulin free human serum albumin (HSA), human apo-transferrin (TFN), and alcohol de-
hydrogenase from Saccharomyces cerevisiae (YAD) from Sigma-Aldrich. The lipopolysac-
charide (LPS) contamination of proteins was determined in a bioassay in which the ability
of proteins to stimulate polymyxin B-sensitive tumour necrosis factor (TNF)-α production
in macrophages was compared with effects of different concentrations of LPS. According to
this assay, the LPS contamination of YAD was ~10 ng/mg protein. OVA, TFN and HSA
seemed free of significant microbial contamination as they did not stimulate TNF-α
production in macrophages even at 100 μg/ml. The LPS contamination of YAD was de-
creased to ~4 ng/mg protein by incubation with polymyxin B-agarose beads, as described
previously [13].
For modification with hypochlorite, proteins were dissolved at 2 mg/ml in PBS (pH 7.4)
and incubated at 37°C for 2 h with 3 mM (OVA, HSA, BSA, TFN) or 2 mM (YAD) NaOCl
(Sigma-Aldrich). The corresponding HOCl:protein molar ratios were: 68:1 (OVA), 100:1
(HSA and BSA), 115:1 (TFN) and 141:1 (YAD homotetramer). Alternatively, in order to
produce more or less heavy oxidation, OVA was incubated with, respectively, 6 mM
(OVA-ClH) or 1 mM (OVA-ClL) NaOCl. The NaOCl concentration was determined before
each reaction by absorbance measurements at 292 nm, using a molar extinction coefficient
of 350 M-1 cm-1. To stop the reaction, the samples were treated with supra-stoichiometric
amounts of thiosulphate (POCH) and then subjected to extensive, 24-h dialysis in PBS at
2–8°C. Modified proteins were aliquoted and stored at -80°C for no longer than 2 months.
Glycolaldehyde-modified BSA (GA-BSA) was prepared as described previously [13].
Other reagents
Rat anti-mouse scavenger receptor A (SR-A) mAb (clone 2F8) was obtained from AbD Sero-
tec; mouse anti-mouse CD36 mAb (CRF D-2712) from Hycult Biotech; mouse IgA isotype
control mAb (M18-254), rat IgG2b isotype control mAb (A95-1), rat anti-mouse CD11b
mAb (M1/70) and phycoerythrin (PE)-streptavidin conjugate from BD Biosciences; rat
IgG2a isotype control mAb (54447), normal goat IgG, polyclonal goat anti-mouse CD36,
anti-mouse LOX-1 (lectin-type oxidised LDL receptor-1), anti-human SREC-I (scavenger re-
ceptor expressed by endothelial cells-I) Ab and PE-conjugated rat anti-mouse LOX-1 mAb
(214012) from R&D Systems; polyclonal goat anti-mouse SREC-I, anti-mouse RAGE (recep-
tor for advanced glycation end products), anti-mouse stabilin-1 and rabbit anti-mouse-stabi-
lin-1 Ab from Santa Cruz Biotechnology; PE-conjugated donkey anti-goat IgG Ab from
SouthernBiotech; rat anti-mouse CD206/mannose receptor mAb (MR5D3) and PE-conjugat-
ed goat anti-rat IgG Ab from BioLegend; horseradish peroxidase (HRP)-conjugated rabbit
anti-mouse IgA, F(ab’)2 fragments of goat anti-rat IgG and donkey anti-goat IgG Ab from
Rockland.
Ultrapure LPS from Escherichia coli K12 strain was purchased from InvivoGen; dextran sul-
phate (DS, MW ~500 kDa), mannan from S. cerevisiae (Man) and chondroitin sulphate A sodi-
um salt from bovine trachea (CS) from Sigma-Aldrich. Low endotoxin acetylated LDL
(AcLDL) and moderately oxidised LDL (oxLDL) were obtained from Biomedical Technologies
and Alexa Fluor 488-labelled AcLDL (AF-AcLDL) and DQ-OVA from Invitrogen.
Zymosan depleted with Toll-like receptor 2 (TLR2) agonists was prepared by boiling 0.5
mg/ml zymosan (Sigma-Aldrich) in 10 M NaOH for 30 min, as described previously [14]. De-
pleted zymosan was washed 3 times and stored at -20°C. Heat-killed Staphylococcus aureus
bacteria (ATCC 25923) were provided by Dr. Anna Białecka (Center of Microbiological Re-
search and Autovaccines, Cracow, Poland).
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Mice
Breeding pairs of SR-A-deficient, CD36-deficient, MPO-deficient and OT-II transgenic mice,
all on the C57BL/6 background, as well as wild-type C57BL/6 (WT) and CBA mice were pur-
chased from the Jackson Laboratory. The mannose receptor (MR)-deficient mice were ob-
tained by cross-breeding of heterozygotic MR+/- mice (the Jackson Laboratory). MR-/- mice
were identified in the progeny of MR+/- mice by PCR genotyping, using the protocol and
primers recommended by the Jackson Laboratory. Mice were housed in our facility in microi-
solator cages with filter tops on a 12-h light/dark cycle. This study was carried out in strict ac-
cordance with the recommendations in the Guide for the Care and Use of Laboratory Animals
of the Ministry of Science and Informatization of Poland. The protocol was approved by the I
Local Committee on the Ethics of Animal Experiments of Jagiellonian University (Permit
Number: 83/2009). All surgery was performed under isoflurane anaesthesia, and all efforts
were made to minimize suffering.
Cells
Twelve-sixteen weeks old male mice were quickly euthanized by overdosing of isoflurane va-
pours (Abbott Laboratories) followed by cervical dislocation. Inflammatory peritoneal cells,
elicited with 1.5 ml of 3% Thioglycollate (Difco Laboratories), injected i.p. 4 days earlier, were
washed out with PBS. The cells were re-suspended in FCS-RPMI [RPMI 1640 medium with 25
mMHEPES (Lonza), supplemented with 10% foetal calf serum (FCS, Cytogen), 2 mM stable
L-glutamine (Cytogen), and 0.04 mg/ml gentamycin (KRKA)] and plated in 96- or 24-well tis-
sue culture treated plates. After overnight incubation, non-adherent cells were removed by
washing and adherent macrophages (PEM) were used in experiments described below.
Dendritic cells were differentiated from bone marrow cells of 4–6 weeks old female mice
under the influence of 20 ng/ml rGM-CSF (eBioscience), as described previously [15]. CD11c-
positive DC (BM-DC) were purified from 6-days cultures with the use of magnetic beads (Mil-
tenyi Biotec). In experiments with BM-DC IMDMmedium (Lonza) containing 10% FCS, glu-
tamine and gentamycin (FCS-IMDM) was used.
CHO-K1 cells stably transfected with human CD36 (CRL-2092) and non-transfected
CHO-K1 cells (CCL-61) were obtained from ATCC and cultured in F12 medium (ATCC) sup-
plemented with 10% FCS. The J774A.1 macrophage-like cell line (TIB-67) was cultured in
FCS-RPMI.
In order to prepare single cell suspension, spleens were cut into smaller pieces and minced
between frosted parts of microscopic slides. Tissue debris were separated by passing through
a 70 μm nylon cell strainer (BD Falcon) and the cells were washed twice with PBS.
CD4-positive cells were isolated with the use of magnetic beads (Miltenyi Biotec), according
to the manufacturer’s instruction.
Binding experiments with isolated receptors
Preparation of coated plates and the shared procedures. Unless otherwise stated, 96-well
half-area ELISA plates (Corning Incorporated) were coated overnight at 4–8°C with 50 μl/well
of 20 μg/ml solutions of different proteins in PBS. The next day the plates were washed twice
with 0.05% Tween 20 in PBS (Tween/PBS). All subsequent steps were performed at room tem-
perature. Between addition of consecutive reagents plates were washed 4 times with Tween/
PBS. All recombinant receptors were obtained from R&D Systems. The enzymatic reaction was
performed with the use of TMB Substrate Reagent Set (BD Biosciences) as the HRP substrate.
Recombinant mouse LOX-1 (rLOX-1). Wells were blocked for 1 h with 0.12 ml of 1%
BSA and 5% sucrose in PBS. His-tagged rLOX-1 at 1 μg/ml in 50 μl of PBS supplemented with
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0.1% Tween 20 and 1% BSA was allowed to bind to coated plates for 70 min. rLOX-1 bound to
plates was quantified with 0.9 μg/ml of goat anti-mouse LOX-1 Ab (1 h), followed by 3 μg/ml
of HRP-conjugated donkey anti-goat IgG Ab (1 h) in 1% BSA.
Recombinant mouse MR (rMR). Plates were blocked with 10% FCS in PBS. The wells
were subsequently filled with 50 μl of 2 μg/ml His-tagged rMR in 10% FCS in PBS with Ca and
Mg (Lonza) for 70-min incubation. Bound rMR was detected with either 1:400 dilution of
HRP-conjugated mouse monoclonal IgG1 anti-6×Histidine (R&D Systems, competition exper-
iments with Ab) or with 2.5 μg/ml of rat anti-mouse CD206 mAb (1 h), followed by 0.5 μg/ml
of HRP-conjugated goat anti-rat IgG Ab (1 h) in 10% FCS.
Recombinant human SREC-I (rSREC-I). Plates were blocked with 10% BSA. rSREC-I/
SCARF1 Fc chimera at 1 or 1.5 μg/ml in 10% BSA was added to plates for 1 h. Bound SREC-I
was detected with 1.5 μg/ml of goat anti-human SREC-I Ab (1 h), followed by 4 μg/ml of HRP-
conjugated anti-goat IgG Ab (1 h) in 2% BSA.
Recombinant mouse RAGE (rRAGE). Plates were blocked with 10% FCS. rRAGE Fc chi-
mera at 2 μg/ml in 10% FCS was allowed to bind to coated plates for 70 min. Bound rRAGE
was detected with 4 μg/ml of goat anti-mouse RAGE Ab (1 h), followed by 3 μg/ml of HRP-
conjugated anti-goat IgG Ab (1 h) in 10% FCS.
Recombinant mouse CD36 (rCD36). Plates were blocked with 10% FCS. rCD36/SR-B3
Fc chimera at 2 μg/ml in 10% FCS was allowed to bind to coated plates for 70 min. Bound
rCD36 was detected with 1 μg/ml of goat anti-mouse CD36 Ab (1 h), followed by 2 μg/ml of
HRP-conjugated anti-goat IgG Ab (1 h) in 10% FCS.
Competition experiments. Soluble ligands were pre-incubated for 30 min at room tem-
perature with recombinant receptors before the mixture was added to coated plates. The rest of
procedures was the same as described above.
Binding of natural SR-A. Binding of SR-A, present in a lysate of C57BL/6 PEM, to pro-
tein-coated plates was performed, as described previously by others [16]. Lysate prepared from
SR-A-deficient PEM served as the control for non-specific binding.
Assessment of surface protein expression
Flow cytometry. PEM (detached by 15 min incubation at 37°C with 15 mM lidocaine
(Sigma-Aldrich) plus 5 mM EDTA in PBS), purified BM-DC or unfractionated splenic cells
(2 × 105 leukocytes) were pre-incubated for 30 min on ice in 0.1 ml of FCS-RPMI containing
40% mouse serum and 50 μg/ml of non-immune mouse IgG2a (BD Biosciences), in order to
decrease non-specific binding. Subsequently, 0.1 ml solutions of receptor-specific or control
mAb were added, to give final mAb concentrations of 10 μg/ml, and the incubation was contin-
ued for 50 min. Unbound mAb were removed by washing with 2 ml of ice-cold PBS, and the
cells were incubated for another 50 min with 5 μg/ml of PE-conjugated secondary Ab in 0.2 ml
FCS-RPMI. In order to enable identification of DC and macrophages, splenic cells were sub-
jected to additional incubation with 5 μg/ml of allophycocyanin-conjugated anti-CD11c (clone
N418) or F4/80 mAb (eBioscience), respectively. Following washing twice, binding of fluores-
cently-labelled Ab to cells was assessed by flow cytometry.
The surface expression of MHC-II, CD40 and CD86 was also determined by flow cytome-
try, by direct labelling of these molecules with 5 μg/ml of PE-conjugated MHC-II-, CD40-, or
CD86-specific or isotype-matched control mAb obtained from BD Biosciences or eBioscience.
Cellular ELISA. Expression of CD36 on the surface of adherent CHO cells was deter-
mined by cellular ELISA, as described previously [17]. Primary mAb were used at 10 μg/ml
and HRP-conjugated rabbit anti-mouse IgA Ab at 5 μg/ml.
HOCl Increases Immunogenicity of Proteins
PLOS ONE | DOI:10.1371/journal.pone.0123293 April 7, 2015 5 / 39
Uptake of fluorescently-labelled ligands
Native and HOCl-modified proteins were conjugated with amine-reactive, fluorescent dyes:
Alexa Fluor 647 carboxylic acid or pHrodo Red succinimidyl esters, according to manufactur-
er’s instructions (Invitrogen). Unbound dyes were separated by extensive dialysis. The degree
of labelling was estimated to be ~2:1 in the case of OVA, ~3:1 in the case of HSA and ~7.5:1 in
the case of YAD. Degrees of labelling of HOCl-modified proteins were slightly (4–14%) lower
than those of their native counterparts.
BM-DC (1.5 × 105) were distributed into 5 ml polypropylene round-bottom tubes (BD Fal-
con) and pre-incubated for 20 min at room temperature with double-concentrated solutions of
blocking ligands in 0.2 ml FCS-IMDM: 0.2 mg/ml AcLDL, oxLDL, DS or CS, 6 mg/ml mannan,
1 mg/ml native or HOCl-modified unlabelled proteins, 40 μg/ml receptor-specific or isotype-
matched control Ab. Subsequently, 0.2 ml of solutions of fluorescently-labelled proteins were
added (the final concentration 5 μg/ml) and the incubation was continued for 1 h (Alexa Fluor
647-labelled ligands) or 2 h (pHrodo-labelled ligands) in a cell culture incubator. Unbound li-
gands were removed by washing twice with 1 ml PBS, and the cell-associated fluorescence was
quantified by flow cytometry. In the case of pHrodo-labelled ligands, for the measurement the
cells were suspended in PBS which pH was adjusted to 9.0 with 25 mMHEPES, in order to
allow selective quantification of ligands internalised into acidic intracellular compartments. Re-
sults of experiments in which uptake of different proteins was compared were normalized for
differences in degrees of labelling, by dividing by factors equal degree of labelling of a given
protein/degree of labelling of OVA-Cl.
In the case of PEM and CHO cells the uptake experiments were performed on adherent
cells. Peritoneal exudate cells and CHO cells were plated in 24-well plates at 4 and 2 × 105/well,
respectively, and allowed to adhere overnight in 1 ml FCS-RPMI. Adherent cells were incubated
with fluorescently-labelled ligands in 0.6 ml FCS-RPMI, as described above, washed once with
PBS, detached with lidocaine/EDTA and their fluorescence was measured by flow cytometry.
Antigen degradation was assessed with the use of DQ-OVA (Invitrogen). DQ-OVA is a
preparation of OVA which is densely substituted with the BODIPY fluorescent dye. Its fluores-
cence strongly increases upon proteolytic degradation due to de-quenching. BM-DC were pre-
incubated or not with DS or mannan and then allowed to bind 20 μg/ml DQ-OVA during 1-h
incubation on ice. Unbound DQ-OVA was removed by washing twice with ice-cold PBS and
the cells were transferred to a cell culture incubator for 2-h incubation. Fluorescence of cells
(FL1) was measured by flow cytometry.
For assessing effects of receptor ligation on intracellular degradation of antigens, peritoneal
exudate cells and BM-DC were plated at 1.6 and 1.2 × 105/well, respectively, in 96-well Optilux
Black/Clear Bottom plates (BD Biosciences). The next day, adherent cells were incubated for
70 min on ice with 20 μg/ml of DQ-OVA or pHrodo-labelled OVA-Cl (pHr-OVA-Cl). Un-
bound ligands were removed by washing twice, and the cells were incubated for 15 min at 37°C
in medium alone, in order to enable internalisation of ligands, and then for additional 2 h in
medium containing 0.1 mg/ml DS, 2 mg/ml mannan, 20 μg/ml anti-SR-A 2F8 mAb or 200 ng/
ml LPS. Following washing once, cell-associated fluorescence was measured with the use of a
fluorescence plate reader (Infinite M200 PRO, Tecan).
Antigen presentation in vitro
Peritoneal exudate cells were plated at 1 × 105/well of 96-well plates in 0.2 ml FCS-RPMI. BM-DC
were plated at 0.75 × 105/well and incubated overnight in 0.15 ml of FCS-IMDM containing 20
ng/ml GM-CSF. Adherent PEM or BM-DC were incubated for 3.5 h at 37°C with 7 μg/ml
OVA-Cl or 20 μg/ml OVA in 0.2 ml of FCS-RPMI or FCS-IMDM, respectively. When indicated,
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200 ng/ml of LPS was added for the last 2 h of incubation with antigens. The cells were washed
once with 0.18 ml of fresh medium, and 1 × 105 of CD4+ cells/well, isolated from spleens of OT-II
mice, were added in 0.2 ml of FCS-IMDM, supplemented with 0.05 mM 2-mercaptoethanol and 1
mM sodium pyruvate (Gibco) (the complete FCS-IMDMmedium). Alternatively, freshly-isolated
BM-DC were pulsed for 2 h with different concentrations of OVA or OVA-Cl in polypropylene
tubes, before being washed and used as APC in the co-culture with CD4+ OT-II splenocytes.
Following 1- or 2-days co-incubation, aliquots of culture supernatants were collected for cy-
tokine determinations by standard sandwich ELISA [18]. In some cases, lymphocyte prolifera-
tion was assessed by adding 1 μCi/well of 3H-thymidine (PerkinElmer) for the last 20 h of
culture and quantifying radioactivity incorporated by lymphocytes with the use of a microplate
scintillation counter (MicroBeta TriLux, Wallac). Before the measurement, the cells were har-
vested onto a glass fiber filtermat (Wallac) and after drying the filters were melted in a solid
scintillator (Meltilex, PerkinElmer).
In the experiments aimed at elucidation of mechanisms of antigen presentation, 2.5 × 105 of
purified BM-DC were co-incubated with 7.5 × 105 of CD4-positive OT-II splenocytes and
10 μg/ml OVA or OVA-Cl for 2 days in 1 ml of complete FCS-IMDMmedium in 24-well
plates. To block MHC-II, DC were pre-incubated for 30 min at room temperature with func-
tional grade-purified, biotinylated rat anti-mouse MHC-II mAb (clone M5/114.15.2,
eBioscience), before being added to the co-culture (final mAb concentration 5 μg/ml). To block
CD40L, Th lymphocytes were pre-incubated for 30 min with no azide/low endotoxin hamster
anti-mouse CD154 mAb (clone MR1, BD Biosciences; 25 μg/ml). Cytokine concentrations in
culture supernatants were determination by ELISA. Adherent BM-DC were detached with li-
docaine/EDTA, combined with non-adherent cells, and expression of MHC-II, CD40 and
CD86 on BM-DC, distinguished thanks to co-staining with allophycocyanin-conjugated anti-
CD11c mAb (HL3, BD Biosciences), was determined as described above, except that biotiny-
lated anti-MHC-II followed by PE-conjugated streptavidin, instead of directly PE-labelled anti-
MHC-II mAb, was used to determine the expression level of MHC-II.
Presentation of neutrophils-modified OVA
Assessing production of reactive oxygen species. Lucigenin-enhanced chemilumines-
cence is known to be caused by extracellular superoxide anion [13]. In contrast, luminol-en-
hanced chemiluminescence is not as selective but it depends on HOCl formation [19].
Peritoneal exudate cells, elicited with 1.5 ml of 3% Thioglycollate, injected i.p. 18 h earlier and
consisting mainly of neutrophils [20], were washed out with PBS and re-suspended in Ca/ Mg-
and glucose-containing Hanks' balanced salt solution (HBSS, Lonza) at 1 × 107/ml. Wells of
96-well plates (F16 Black MaxiSorp, Nunc) were filled with 100 μl of cell suspension, 50 μl of
luminol (the final concentration 0.5 mg/ml) or lucigenin (0.2 mg/ml) solution in HBSS
(Sigma-Aldrich) and 50 μl HBSS with or without 5 kU/ml bovine SOD (Calbiochem) or 0.5
mM 4-aminonbenzoic acid hydrazide (ABAH, Sigma-Aldrich). After 25 min incubation at
37°C in a cell culture incubator, 50 μl of zymosan (0.2 mg/ml) or heat-killed S. aureus
(75 × 106/ml) was added and then immediately chemiluminescence was recorded for 75 min in
a temperature-stabilised (37°C) luminometer (Lucy 1, Anthos).
Presentation of neutrophils-modified OVA by PEM in vitro. Peritoneal exudate cells
were plated at 1.8 × 105/well in 96-well plates. The next day, PEM were co-incubated for 2 h 15
min in a cell culture incubator with 2.5 × 106/ml neutrophils, 75 × 106/ml heat-killed S. aureus
and 25 μg/ml OVA in 0.2 ml of HBSS. When indicated, 5 kU/ml of SOD was additionally in-
cluded in the incubation mixture. Fifty μl of 50 mM EDTA was added for the last 15 min of in-
cubation to facilitate detachment of neutrophils, and the majority of neutrophils, together with
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free bacteria and OVA, were removed by extensive washing. PEM were then incubated for 24 h
with 2 × 105/well OT-II Th lymphocytes in 0.2 ml of complete FCS-IMDMmedium.
In vivo antibody production
WT and MPO-/- mice were immunized by i.p. injection with 1 ml of PBS with Ca/Mg, contain-
ing 20 μg HSA, OVA or YAD and an adjuvant. As adjuvants: 0.2 mg of depleted zymosan,
2 × 108 heat-killed S. aureus, 2 μg Pam3CSK lipopeptide (InvivoGen), 2 μg LPS or 50 ng recom-
binant mouse TNF-α (eBioscience) plus 1.7 μg WKYMVm peptide (a synthetic agonist of re-
ceptors for chemotactic formylated peptides, Tocris) per ml per mouse were used. WT,
SR-A-/- and CD36-/- mice were immunized with 20 μg and CBA mice with 10 or 100 μg of
proteins in 1 ml PBS. Fourteen days later some mice received second i.p. injection with 20 μg of
native proteins alone in 0.5 ml PBS. Blood was collected 8 days after first (primary response) or
second (secondary response) immunization.
Titers of specific immunoglobulins in sera were determined as follows. Half-area ELISA
plates were coated with 50 μl/well of 10 μg/ml proteins in PBS by overnight incubation at
4–8°C. The next day the plates were washed twice with Tween/PBS and blocked for 1 h with
10% FCS. Eight 3-fold serial dilutions of sera were prepared, starting from 1:5 or 1:10, and
added to plates for 1-h incubation at room temperature. One % BSA in PBS served as the re-
agent diluent. Following washing, the wells were filled for 45 min with 26 μl of biotin conjugated
isotype-specific Ab: 25 ng/ml goat anti-mouse IgG Ab, 50 ng/ml goat anti-mouse IgG2a Ab,
100 ng/ml goat anti-mouse IgM Ab (SouthernBiotech) or 1:20,000 dilution of rat anti-mouse
IgG1 Ab (ICN Biomedicals). Subsequently, 50 μl of 1 μg/ml (total IgG, IgG1 and IgM assays) or
0.5 μg/ml (the IgG2a assay) streptavidin-HRP conjugate (Vector Laboratories) was added for
45 min. The plates were subjected to the final washing (4 times) and the enzymatic reaction for
peroxidase was performed with the use of 3.5 mMH2O2 and 0.5 mg/ml o-phenylenediamine
dihydrochloride (Sigma-Aldrich) in 0.1 M phosphate-citrate buffer (pH 5.0) as substrates. Thir-
ty min later the reaction was stopped with 3MH2SO4 and absorbance at 492 nm of the product
was measured with the use of a plate reader (PowerWave, Bio-Tek Instruments). In parallel,
non-specific binding to wells not coated with antigens was determined for each dilution of
serum and subtracted from the total binding. This calculated specific binding was plotted as the
function of logarithm of serum dilution. The titer was defined as the dilution of serum which
binds specifically with the absorbance value of 0.2 and was determined by fitting a sigmoidal
dose-response non-linear regression curve with the use of GraphPad Prism software.
Data analysis
After confirming homogeneity of variances with the F test, experimental groups were com-
pared with control groups with the Student’s t-test (GraphPad Prism software) and the p
values< 0.05 were assumed to denote statistically significant difference. One way ANOVA was
applied for multiple comparisons, with the Tukey-Kramer post-test used to compare all pairs
of groups, the Bonferroni test used to compare selected groups, and the Dunnett’s test to com-
pare all other groups to the control group.
Results
Increased immunogenicity of OVA-Cl may be caused by its enhanced
uptake by APC
Previously, OVA-Cl has been shown to be presented effectively by BM-DC to memory Th lym-
phocytes [12], known to be more easily activated than naïve lymphocytes. We have found that
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BM-DC, pre-incubated for 2 h with OVA-Cl, are also able to stimulate proliferation of naïve
Th lymphocytes (Fig 1A). In the presence of LPS, lymphocyte proliferation during 2 days of
co-culture was stimulated by lower concentrations of OVA-Cl than OVA (Fig 1A, left panel).
During 3-days co-culture the difference in the sensitivity of detection between OVA and
OVA-Cl disappeared, but OVA-Cl stimulated more intense proliferation of CD4+ lymphocytes
than OVA in the entire range of concentrations tested (Fig 1A, right panel). In contrast, in the
absence of LPS, OVA-Cl was effectively presented to lymphocytes at a concentration as low as
5 μg/ml, whereas OVA did not stimulate lymphocyte proliferation even at 20 μg/ml (Fig 1A).
It is believed that except of specific recognition of antigen-MHC complexes on the surface
of DC, activation of naïve lymphocytes during antigen presentation requires additional stimuli,
provided by co-stimulatory molecules on the surface of DC (second signal) and by DC-derived
cytokines (third signal). However, we found that, in contrast to LPS, neither OVA nor OVA-Cl
Fig 1. OVA-Cl exhibits increased immunogenicity that may be caused by enhanced uptake by APC. (A) BM-DC were incubated with indicated
concentrations of OVA or OVA-Cl for 2 h at 37°C. When indicated, 200 ng/ml LPS was additionally included. Following washing, 0.4 × 105 BM-DC were co-
cultured for 2 or 3 days with 1.5 × 105 CD4+ OT-II lymphocytes. One μCi of 3H-thymidine was added for the last 20 h of co-culture and radioactivity
incorporated by proliferating lymphocytes was measured by scintillation counting. (B) BM-DC were incubated for 1 h at 37°C with indicated concentrations of
Alexa Fluor 647-labelled OVA (AF-OVA) or OVA-Cl (AF-OVA-Cl) and, following washing, cell-associated fluorescence was measured by flow cytometry. (C)
Unfractionated splenocytes, prepared from spleens of OT-II mice, we pre-incubated with OVA, OVA-Cl and LPS, as described in A, washed, plated at
2.5 × 105/well in 0.2 ml of fresh medium and cultured for 2 days, for assessing lymphocyte proliferation, or 3 days, for assessing IFN-γ level in culture medium
by ELISA. Results shown on graphs A-C are averages ± SEM of 2 (B), 3 (A) or 4 (C) replicates, obtained in single experiments which were repeated at least 3
times with similar results. (D) Expression of MHC-II and co-stimulatory molecules on the surface of BM-DC as well as splenic DC and macrophages was
determined by flow cytometry. When indicated, BM-DC were pre-incubated overnight with LPS. Specific binding was calculated by subtracting binding of PE-
conjugated control mAb from the total binding of specific mAb. The results shown are averages ±SEM from 4–6 independent experiments.
doi:10.1371/journal.pone.0123293.g001
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at concentrations up to 50 μg/ml stimulated cytokine release from BM-DC or affected expres-
sion of MHC-II or co-stimulatory molecules (CD40 and CD86) on their surface (S1 Fig).
Another potential cause of increased immunogenicity of OVA-Cl may be enhanced uptake
and intracellular processing by APC. In order to test this possibility, we labelled OVA and
OVA-Cl with the Alexa Fluor 647 fluorescent dye (AF) and studied their uptake by APC. We
found that both PEM (Fig 2B) and BM-DC (Fig 1B) endocytosed much more AF-OVA-Cl
than AF-OVA. Of note, stimulation of lymphocyte proliferation in the presence of LPS corre-
lated with the level of antigen uptake (compare Fig 1A, left panel, and 1B). Thus, it seems that
in the presence of LPS the major limiting factors in antigen presentation are amounts of endo-
cytosed antigens and the ability of BM-DC to process and present these antigens. Consistent
with this interpretation, increasing the duration of co-culture to 3 days resulted in the shift of
OVA-Cl concentrations producing the maximal effect to higher concentrations (Fig 1A, right
panel). In contrast, there was no correlation between antigen uptake and lymphocyte prolifera-
tion in the absence of LPS (Fig 1A and 1B), which indicates that also factors other than en-
hanced uptake contribute to increased immunogenicity of HOCl-modified OVA.
Stimulation of pattern recognition receptors on APC is not required for
triggering of primary immune response to OVA-Cl
Efficient presentation to naïve CD4+ lymphocytes by DC of protein antigens alone, not contam-
inated with microbial products, is inconsistent with the currently dominating paradigm, ac-
cording to which such presentation requires activation of pattern-recognition receptors (PRR)
on DC [21]. As DC activation might be caused by GM-CSF used in the culture of BM-DC, we
decided to assess whether OVA-Cl alone would also be able to initiate immune response in the
culture of splenocytes isolated from naïve OT-II mice. Also in the culture of unfractionated
splenocytes OVA-Cl stimulated proliferation of lymphocytes which was higher than that stimu-
lated by OVA (Fig 1C, left panel). There were, however, two major differences with previous ex-
periments employing BM-DC. First, in the case of unfractionated splenocytes proliferation was
also stimulated by native OVA. This difference might be caused by higher expression of endocy-
tic receptors on splenic DC than on BM-DC or the presence among splenocytes of other cell
types. Consistent with the former possibility, also BM-DC effectively presented OVA when they
were allowed to endocytose it for a longer period (Fig 3C). Second, unlike in the co-culture with
BM-DC, in unfractionated splenocytes lymphocyte proliferation was not enhanced by LPS.
However, under these conditions LPS did promote differentiation of naïve T lymphocytes to-
wards Th1 cells, as indicated by strongly increased interferon-γ (IFN-γ) production. Interest-
ingly, very high IFN-γ production was also stimulated by OVA-Cl alone, which was not only
higher than that stimulated by OVA alone but also by OVA plus LPS (Fig 1C, right panel).
Mechanisms of immunostimulation exerted by PRR agonists are thought to involve up-reg-
ulation of MHC and co-stimulatory molecules expression on DC, known as maturation. There-
fore, attempting to identify factors responsible for differences in APC functions between
splenic APC and BM-DC, we examined expression of these molecules on both cell types. We
found that splenic DC, defined in flow cytometry as large cells with high expression level of
CD11c, expressed as much as ~4-times more of both MHC-II and CD40 than BM-DC. Expres-
sion of these molecules on BM-DC was similar to that on splenic F4/80-positive macrophages
(Fig 1D). Treatment with LPS induced strong expression of CD40 and CD86 as well as up-reg-
ulated expression of MHC-II on BM-DC to the level seen on splenic DC. Thus, BM-DC, but
not splenic DC, may require up-regulation of MHC-II expression for optimal antigen presenta-
tion, which might explain why LPS enhances proliferation of lymphocytes in the co-culture
with BM-DC, but not in the suspension of unfractionated splenocytes.
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In order to gain insight into mechanisms of this efficient Ag presentation in the absence of
PRR ligands, we assessed effects of co-culturing BM-DC and OT-II CD4+ T cells, with or with-
out OVA antigens, on the expression of MHC-II and co-stimulatory molecules on BM-DC as
well as on cytokine release. Even in the absence of specific antigens, 2-days co-culture of
Fig 2. Humoral immune response stimulated by native and HOCl-oxidised proteins in vivo. (A, C, D)
CBAmice were immunized with the indicated antigens. Two weeks later all mice received boost
immunization with 20 μg of native proteins and 8 days later sera were collected for the determination of titers
of specific Ab by ELISA. Points represent titer values in individual mice and horizontal lines geometric means.
(B) Uptake of fluorescently-labelled ligands by PEM was determined by flow cytometry. The data were
analysed by ANOVA and the Benferroni post-test was applied to compare the indicated pairs of columns. *,
p< 0.05; NS, non-significant.
doi:10.1371/journal.pone.0123293.g002
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BM-DC with CD4+ T lymphocytes resulted in slight up-regulation of CD40 and CD86 expres-
sion on BM-DC (Fig 4A). BM-DC also spontaneously released interleukin (IL)-12p40 subunit,
but no production of IL-2 and IFN-γ was observed in the absence of antigen (Fig 4B). Inclusion
of OVA in the co-culture led to strong up-regulation of MHC-II and co-stimulatory molecules
expression on BM-DC, enhanced IL-12p40 and induced IL-2 and IFN-γ secretion. In compari-
son to OVA, OVA-Cl induced much higher CD40 expression as well as IL-2 and IFN-γ secre-
tion, but similar MHC-II and CD86 expression. Despite stimulating much higher IFN-γ
production, OVA-Cl stimulated similar IL-12p40 production as OVA. Moreover, no detectable
production of bioactive IL-12p70 was observed in the co-culture, which, together, indicate that
in this system IFN-γ production is IL-12-independent. The role of recognition of peptide-
MHC-II complexes on BM-DC by Th lymphocytes as well as of CD40-CD40L interactions in
Fig 3. Effects of SR-A or CD36 deficiency on antigen uptake, expression of endocytic receptors and antigen presentation to CD4+ OT-II
splenocytes. (A, D) Uptake of indicated, fluorescently labelled proteins, present at 5 μg/ml by BM-DC (A) and PEM (D) was assessed by flow cytometry. (B,
E) Specific binding of Ab to receptors (geometric mean fluorescence intensity) on BM-DC (B) and PEM (E) which was obtained by subtracting binding of
control Ab from the total binding of receptor-specific Ab. (C, F) IL-2 production in 1- or 2-days co-cultures of BM-DC (C) or PEM (F) with CD4+ OT-II
lymphocytes. Directly before the co-incubation with lymphocytes, APC were pulsed for 3.5 h with 20 μg/ml OVA or 7 μg/ml OVA-Cl. The data shown on
graphs A-G are means +SEM from 6–8 independent experiments. (H) Titers of OVA- or HSA-specific IgM in sera of mice immunized 8 days earlier with 20 μg
OVA-Cl or HSA-Cl. Points represent titer values in individual mice and horizontal lines geometric means. The data were analysed with the regular (H) or
repeated measures (A-G) ANOVA and the Dunnett’s post-test was used to make comparisons with the control groups (WT). *, p< 0.05.
doi:10.1371/journal.pone.0123293.g003
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Fig 4. Expression of MHC-II and co-stimulatory molecules on BM-DC (A) and cytokine production (B)
in the co-culture of BM-DCwith OT-II Th lymphocytes. Purified BM-DC (2.5 × 105) were co-cultured with
CD4+ OT-II splenocytes (7.5 × 105) for 2 days in 1 ml of medium, with or without 10 μg/ml OVA or OVA-Cl.
When indicated, 5 μg/ml of blocking anti-MHC-II mAb or 25 μg/ml anti-CD40L mAb was additionally included.
Expression of proteins on BM-DC surfaces was assessed by flow cytometry and cytokine concentration in
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the observed phenomena was assessed with the use of blocking mAb. Blocking MHC-II re-
versed completely OVA-Cl-stimulated increases of MHC-II and CD86 expression (Fig 4A) as
well as of IL-2, IFN-γ and IL-12p40 secretion (Fig 4B). Surprisingly, while anti-MHC-II mAb
blocked recognition of peptide-MHC-II complexes by Th lymphocytes, binding of this mAb to
BM-DC gave rise to selective activation of these cells, reflected by very strong up-regulation of
CD40, but not MHC-II or CD86 expression, and IL-2 production by BM-DC themselves. Act-
ing on BM-DC anti-MHC-II mAb also induced production of IL-12p70, likely related to the
induction of IFN-γ production in these cells. In turn, blocking interactions between CD40 and
CD40L with the use of anti-CD40L mAb, largely reversed the OVA-Cl-stimulated up-regula-
tion of CD86, but not CD40 expression, and OVA-Cl-stimulated IL-12p40 and IFN-γ secre-
tion, but had no such effect on IL-2 production.
For assessing the type of immune responses stimulated by OVA-Cl in vivo, we have chosen
the CBA strain of mice because the IgG2a isotype of Ab is not produced by the C57BL/6 mouse
strain [22]. However, immunization with native OVA induced already very high production of
OVA-specific Ab, which was higher than that induced by OVA-Cl (Fig 2A). These results con-
firm what was already suggested in a previous report [12] that, unlike the epitope recognized
by the transgenic TCR of OT-II lymphocytes, some other epitopes present in OVA are de-
stroyed by HOCl-mediated oxidation. Consistent with this interpretation, immunization of
mice with less heavily oxidised OVA-ClL (which was treated with 1 mM instead of 3 mM
HOCl) induced much higher (~56-times) titers of OVA-specific Ab than OVA-Cl (Fig 2C), de-
spite the fact that the uptake of AF-OVA-ClL by APC was indistinguishable from that of AF-O-
VA-Cl (Fig 2B). In contrast, HSA, which uptake by APC was much lower than that of OVA
(Fig 3A), stimulated very low production of specific Ab, but upon oxidation its immunogenici-
ty dramatically increased, as indicated by on average more than 500-times higher titer of HSA-
specific IgG. At this low dose (10 μg) both native and HOCl-oxidised proteins stimulated
Th2-polarised humoral responses, as indicated by much higher production of specific IgG of
the IgG1 than the IgG2a isotype (Fig 2C and 2D). Increasing the dose of OVA-ClL during
priming, from 10 to 100 μg, not only increased the magnitude of humoral response (~8-times),
but also caused its Th1-polarization, as titers of the IgG1 isotype increased only ~4-times,
whereas those of the IgG2a isotype as much as ~80-times (Fig 2C). In contrast, increasing the
dose of HSA-ClL affected neither the magnitude nor the polarization of humoral response (Fig
2D). Surprisingly, the use of LPS as the adjuvant did not reverse the Th2 polarisation of
HSA-ClL- or OVA-ClL-stimulated immune response.
Increased binding to DC is a shared feature of different chlorinated
proteins and glycoproteins
Uptake of both AF-OVA and AF-OVA-Cl was inhibited more strongly by unlabelled OVA-Cl
than by unlabelled OVA (Fig 5A, left panel). This mutual cross-competition indicates that
OVA and OVA-Cl bind to shared receptors, exhibiting higher affinity for OVA-Cl as com-
pared to OVA.
Next, we assessed whether also other chlorinated proteins exhibit increased binding to
BM-DC by testing their ability to compete with the binding of AF-OVA-Cl. It has been sug-
gested in a previous report of Prokopowicz et al. that oxidised oligosaccharides present in
culture supernatants by ELISA. The results shown are averages +SEM from 4 independent experiments (A)
or means +SEM of 4 replicates obtained in a single, representative experiment (B). The data were analysed
by ANOVA, combined with the Tukey-Kramer post-test. *, p< 0.05.
doi:10.1371/journal.pone.0123293.g004
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OVA-Cl are responsible for its increased binding to BM-DC [12]. However, we found that
chlorinated bovine serum albumin (BSA-Cl), which is not a glycoprotein, competed effectively
with the binding of AF-OVA-Cl, whereas native BSA was ineffective in this regard (Fig 5A). As
BSA is a lipid transport protein and oxidised lipids in oxLDL are known to contribute to
oxLDL binding to endocytic receptors (SR) [23], there was a possibility that such oxidised lip-
ids are also responsible for increased binding of BSA-Cl to BM-DC. However, fatty acid-free
HSA-Cl competed with the binding of AF-OVA-Cl to BM-DC with a similar effectiveness as
BSA-Cl (Fig 5A, right panel). These results indicate that oxidation of amino acid residues them-
selves is sufficient to confer on proteins increased binding to endocytic receptors on BM-DC.
Also chlorinated human apo-transferrin (TFN-Cl) competed strongly with AF-OVA-Cl bind-
ing to BM-DC, whereas native TFN produced little inhibition (Fig 5A, right panel).
Fig 5. OVA and OVA-Cl bind to the same receptors, which are inhibited bymannan (Man), DS and CS and also shared with other HOCl-modified
proteins and glycoproteins. (A, B, C) BM-DC were pre-incubated for 20 min with 1 mg/ml of indicated unlabelled proteins (A), 6 mg/ml Man, 0.2 mg/ml DS
or CS (B, C) before the same volume of double-concentrated solution of AF-OVA or AF-OVA-Cl was added to give the final concentration of 5 μg/ml and the
incubation was continued for 1 h (A, B) or 2 h (C) in a cell culture incubator. Following washing, cell-associated fluorescence was quantified by flow
cytometry. (D) BM-DC were incubated for 1 h with 5 μg/ml AF-OVA-Cl, washed and either directly assessed for antigen uptake or incubated for another 1 h in
medium alone before the cell-associated fluorescence was measured. (E) Following pre-incubation with DS or Man, BM-DC were incubated for 1 h on ice
with 20 μg/ml DQ-OVA. Unbound DQ-OVA was washed out and the cells were either directly assessed for DQ-OVA binding (“4°C”) or transfer to 37°C for 2 h
before the measurement. Results shown are averages ± SEM of triplicates obtained in single experiments, each repeated at least 3 times with similar results.
Statistical analysis was performed with ANOVA, followed by the Tukey-Kramer post-test (A-C, E) or with the Student’s t-test (D). *, p< 0.05; NS, non-
significant.
doi:10.1371/journal.pone.0123293.g005
HOCl Increases Immunogenicity of Proteins
PLOS ONE | DOI:10.1371/journal.pone.0123293 April 7, 2015 15 / 39
Effects of competitive ligands reveal that uptake of OVA and OVA-Cl is
mediated by two major classes of receptors
Attempting to identify specific receptors responsible for OVA-Cl uptake by BM-DC, we begun
from examining effects of general blockers of major endocytic receptors: mannan, a ligand of
MR, DS, a non-selective inhibitor of SR, and of CS, a chemically similar to DS control polya-
nion which does not bind to SR [24]. Both DS [25] and CS [26] were also reported to be ligands
of MR. DS strongly inhibited uptake of both AF-OVA and AF-OVA-Cl (Fig 5B). A weaker in-
hibition was produced by mannan and CS. In dose-response experiments, mannan at 3 mg/ml
and DS at 0.1 mg/ml exerted already maximal effects, corresponding to ~50% and ~90% inhibi-
tion of OVA-Cl (5 μg/ml) uptake (Fig 5B). Importantly, the combination of mannan and DS
did not inhibit more strongly OVA-Cl uptake than DS alone. These results indicate that
OVA-Cl uptake by BM-DC is mediated by two types of receptors: the first one inhibited by
both mannan and DS and accounting for ~50% of total OVA-Cl uptake, and the second one,
inhibited by DS but not mannan, and responsible for ~40% (90–50) of the uptake.
Interestingly, when BM-DC were allowed to endocytose AF-OVA-Cl for a longer time, for 2
h instead of 1 h, the potency of mannan to inhibit AF-OVA-Cl uptake slightly increased and
that of DS strongly decreased (Fig 5C). Among possible explanations of these results is that
AF-OVA-Cl undergoes more intense degradation when internalised through receptors inhib-
ited by DS, but not by mannan, as compared to when internalised through receptors inhibited
by both competitors. Supporting this interpretation, when BM-DC were first pulsed with
AF-OVA-Cl for 1 h and then incubated for an additional hour in medium alone, their fluores-
cence decreased by ~30%, being indicative of intracellular degradation of endocytosed AF-O-
VA-Cl (Fig 5D). More intense degradation of ligands internalised through receptors blocked
by DS only has been confirmed in experiments with DQ-OVA. Degradation of DQ-OVA was
strongly inhibited by receptor blockade with DS, but only by ~24% by mannan (Fig 5E).
Endogenous, neutrophils-derived HOCl is capable of increasing
immunogenicity of proteins
The results presented above confirm that treatment with HOCl added as a reagent increases
immunogenicity of OVA. The purpose of the next series of experiments was to verify the physi-
ological significance of this process, i.e. evaluating the possibility that oxidation by endogenous
HOCl, produced by activated neutrophils, leads to increased immunogenicity of proteins. For
this purpose, adherent PEM were co-cultured with neutrophils in the presence of native OVA.
Production of HOCl in neutrophils was induced by heat-killed S. aureus. As shown in Fig 6A,
both the bacteria and zymosan stimulated ~10-times stronger luminol chemiluminescence in
WT than in MPO-/- neutrophils (as estimated by calculating the areas under curves), confirm-
ing that chemiluminescence under these conditions depends on MPO activity. Consistently,
the zymosan-stimulated luminol chemiluminescence in WT neutrophils was inhibited in
~63% by 0.5 mM ABAH, an inhibitor of MPO. In contrast, both zymosan (Fig 6A, right panel)
and S. aureus (S2 Fig) stimulated ~2-fold stronger lucigenin chemiluminescence in MPO-/-
than in WT neutrophils. Zymosan-stimulated lucigenin chemiluminescence was quenched
completely by 5 kU/ml SOD (Fig 6A, right panel), but unaffected by ABAH (S2 Fig), confirm-
ing the major role of extracellular O2
- in generating lucigenin chemiluminescence.
Like BM-DC, PEM presented more effectively OVA-Cl than OVA (Fig 6B). Both OVA- and
OVA-Cl-stimulated IL-2 production in the co-culture was enhanced by S. aureus. The inclu-
sion of WT neutrophils during pre-incubation of PEM with OVA significantly increased IL-2
production by subsequently added Th lymphocytes, but only when S. aureus, a trigger of respi-
ratory burst, was also present. In contrast, no such effect was produced by MPO-/- neutrophils,
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Fig 6. Immunogenicity of proteins is enhanced as the result of oxidation by endogenous, neutrophils-derived HOCl. (A) Luminol- or lucigenin-
enhanced chemiluminescence stimulated by zymosan (Zym) or heat-killed S. aureus (Sa) in WT and MPO-/- neutrophils. (B) Presentation of OVA, as
assessed by IL-2 production, by PEM pre-incubated with OVA, S. aureus andWT or MPO-/- neutrophils (PMN) to subsequently added CD4+ OT-II
lymphocytes. (C) Uptake of pHrodo-labelled native or HOCl-oxidised YAD or HSA by BM-DC, assessed by flow cytometry. Results of single experiments
shown were repeated 2 more times with similar results. (D) Titers of YAD-specific IgG in sera of mice primed with 20 μg YAD and hot alkali-treated zymosan
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despite the above shown, much higher production of O2
- in these cells. These results indicate
that neutrophils are able to convert native OVA to more immunogenic forms and that HOCl is
the oxidant responsible for this modification. The role of HOCl is further supported by the en-
hancing effect on OVA immunogenicity of SOD, an enzyme that depletes O2
-, but increases
the level of H2O2, a substrate in MPO-catalysed HOCl production. Interestingly, WT, but not
MPO-/- neutrophils also increased immunogenicity of OVA-Cl (Fig 6B).
In order to assess the role of HOCl-mediated oxidation of proteins in vivo, we immunized
WT and MPO-/- mice with 20 μg of native HSA together with hot alkali-treated zymosan as a
trigger of neutrophil influx and the respiratory burst in these cells. Two weeks later mice were
given, also by i.p. route, boost immunization with 20 μg HSA alone and sera were collected for
Ab determination 8 days later. It turned out that in MPO-/- mice immunization with HSA plus
zymosan did not stimulate lower, but rather tended to stimulated higher production of specific
Ab than in WTmice (S3 Fig, top and middle panels). Similar results were obtained when OVA
was used as the antigen (S3 Fig, bottom panel). Strong up-regulation of several immune mecha-
nisms in MPO-/- mice have been already reported [27]. We hypothesized that our failure to
demonstrate the role of MPO-mediated oxidation of protein antigens in vivo may be caused by
the fact that the vertebrate proteins used by us bind to endocytic receptors also in their native
forms. We therefore decided to use yeast alcohol dehydrogenase (YAD) as the antigen. As
shown in Fig 6C, unlike native HSA and HOCl-oxidised YAD, native YAD was not endocy-
tosed by BM-DC. Immunization with native YAD alone induced no or very low titers of specif-
ic IgG in both WT and MPO-/- mice (Fig 6D). However, co-administration of YAD with
depleted zymosan induced on average 9.5 (total IgG)– 21.6 (IgG1)-times higher titers of YAD-
specific Ab in WT than in MPO-/- mice, confirming that oxidation by neutrophils’MPO is
able to increase immunogenicity of proteins also in vivo. We have suspected that the residual
low-level Ab production which has persisted in MPO-/- mice might be caused by the acquisi-
tion of proteins by APC as the result of co-uptake together with porous, hollow zymosan parti-
cles [28]. We therefore used soluble inducers of acute inflammation—a mixture of TNF-α and
the WKYMVm peptide as an adjuvant. Co-administration of this non-phagocytosable adju-
vant with YAD enhanced significantly the humoral response only in WT, but not in MPO-/-
mice (Fig 6D, left panel), demonstrating the critical role of HOCl-mediated oxidation in con-
ferring immunogenicity on exogenous proteins.
Scavenger receptors A (CD204) and CD36 are responsible for the
portion of OVA-Cl uptake inhibited by DS, but not by mannan
Stronger inhibition of AF-OVA-Cl uptake by DS than by CS suggests an involvement of SR
in this process. Amongst them, the class B SR CD36 has been demonstrated to serve as a re-
ceptor for HOCl-oxidised LDL [29]. Aiming to examine the role of CD36 as a receptor for
OVA-Cl, we compared uptake of AF-OVA-Cl by CHO cells transfected or not with CD36.
Surprisingly, non-transfected CHO cells exhibited both the pattern and magnitude of fluores-
cently-labelled ligands uptake very similar to BM-DC and transfection with CD36 did not
have any effect on this uptake (Fig 7A). These results indicate that either CD36 is not a recep-
tor for OVA-Cl or that endogenous receptors of CHO cells are already sufficient to mediate
the maximal uptake, which therefore cannot be further increased by overexpression of CD36.
or TNF-α plus WKYMVm peptide and boosted 2 weeks later with 20 μg of YAD alone. Sera were collected 8 days after the boost immunization and titers of
YAD-specific IgG were determined by ELISA. Points represent titer values in individual mice and horizontal lines geometric means. Statistical analysis was
performed with ANOVA, followed by the Tukey-Kramer post-test, to compare all pairs of groups (B, D) or by the Dunnett’s test, to make comparisons with the
control group (“Autofluor.”) (C). *, p< 0.05; NS, non-significant.
doi:10.1371/journal.pone.0123293.g006
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Supporting the latter possibility, we detected specific binding of anti-CD36 mAb to non-
transfected CHO cells (Fig 7B). Thus, results of experiments with transfected cells are incon-
clusive regarding the role of CD36 as OVA-Cl receptor. We therefore resorted to a different
approach, namely studying binding of isolated rCD36 to proteins adsorbed to ELISA plates.
As shown in Fig 7C, rCD36 bound strongly to immobilized GA-BSA and AcLDL, used as
positive controls. The binding of rCD36 to OVA-Cl, TFN-Cl and HSA-Cl was as high as to
GA-BSA. In contrast, rCD36 did not exhibit specific binding to native proteins. Binding of
Fig 7. Roles of SR CD36 (A-E) and SR-A (G-I) as receptors for HOCl-modified proteins. (A) Uptake of fluorescently-labelled proteins by CHO cells
transfected with human CD36 as compared to non-transfected cells. (B) Binding of anti-CD36 mAb and control mouse IgA to CD36-transfected and non-
transfected CHO cells, determined by cellular ELISA. (C) Binding of rCD36 to plate-adsorbed proteins. (D) Effects of 10 or 100 μg/ml of indicated, soluble
ligands on rCD36 binding to plate-adsorbed OVA-Cl. (E) Binding of polyclonal anti-mouse CD36 Ab and control goat IgG to BM-DC, splenic DC and PEM. A
representative histogram of Ab binding to BM-DC is displayed on the left graph. (F) Binding of anti-mouse SR-A mAb and control rat IgG2b to BM-DC, splenic
DC and PEM. A representative histogram of Ab binding to BM-DC is shown on the left graph. (G) Binding of SR-A present in lysates of PEM to plate-
adsorbed proteins. (H) Effects of anti-SR-A 2F8 mAb and AcLDL on the uptake of fluorescently-labelled proteins by BM-DC. Shown are results of single
experiments, each representative of at least 3 similar experiments performed (A-D, G, H) or averages +SEM from 4–6 independent experiments (E, F). The
data were analysed with the unpaired (A-C, G) or one-sample (H) Student’s t-test or with ANOVA, followed by the Tukey-Kramer post-test (D). *, p< 0.05;
ND, not done.
doi:10.1371/journal.pone.0123293.g007
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rCD36 to adsorbed OVA-Cl was dose-dependently inhibited by soluble DS and GA-BSA, but
not by CS and mannan (Fig 7D), which confirms that rCD36 retains the ligand binding speci-
ficity of natural CD36. Surprisingly, soluble OVA-Cl inhibited rCD36 binding even more po-
tently than DS or GA-BSA, whereas OVA had no effect. These results indicates that upon
oxidation by HOCl proteins gain the ability to bind to CD36 with high affinity.
We started verification of CD36 involvement in OVA-Cl uptake by BM-DC from examin-
ing CD36 expression on these cells. As shown in Fig 7E, CD36 was expressed in ~36% of
BM-DC at low level. At slightly higher level CD36 was also expressed on splenic DC. In con-
trast, PEM exhibited extremely high expression of CD36; specific binding of goat anti-mouse
CD36 Ab to PEM was as much as ~25-fold higher than its binding to BM-DC (Fig 7E). We
then assessed the role of CD36 in OVA-Cl uptake with the use of function-blocking anti-CD36
mAb. This Ab had no effect on AF-OVA or AF-OVA-Cl uptake by BM-DC (S4A Fig).
SR-A has been reported to serve as a receptor for numerous covalently-modified proteins
[30]. BM-DC were confirmed to exhibit expression of SR-A, which was relatively low as com-
pared to CD11b expression (Fig 7F). The expression of SR-A on splenic DC was similar to that
on BM-DC, whereas PEM express ~2-times more SR-A (Fig 7F). In order to examine the role
of SR-A as a receptor for HOCl-modified proteins we took advantage from the method devel-
oped by Peiser et al. [16], in which binding of SR-A present in lysates of macrophages to plate-
adsorbed proteins is examined. As shown in Fig 7G, SR-A bound strongly to GA-BSA, used as
a positive control. In comparison, binding of SR-A to HOCl-modified protein was weak, with
the strongest one to BSA-Cl, and no binding of SR-A to native proteins was observed. These re-
sults indicate that HOCl-oxidised proteins are ligands of SR-A. The role of SR-A in the uptake
of HOCl-modified proteins by BM-DC was then assessed with the use of blocking 2F8 mAb.
Although in BM-DC this mAb at 20 μg/ml inhibited by ~35% uptake of AF-AcLDL, the proto-
type ligand of SR-A, it had no consistent effect on AF-OVA or AF-OVA-Cl uptake (S4B Fig).
At 2-fold higher, 40 μg/ml concentration anti-SR-A mAb also had no significant effect on
AF-OVA-Cl uptake, but inhibited by ~21% uptake of AF-OVA and by ~20% internalisation of
pHr-OVA-Cl (Fig 7H). Anti-SR-A mAb produced even stronger, ~41% inhibition of internali-
sation into acidic compartments of pHr-HSA-Cl, similar to its effect on the uptake of
AF-AcLDL (~45%) (Fig 7H). It seems, however, that effects of even this high concentration of
anti-SR-A mAb underestimate the contribution of SR-A to the uptake of protein ligands as
SR-A deficiency had much stronger effect on these ligands uptake (Fig 3A). Uptake of AF-O-
VA-Cl and internalisation of pHr-OVA-Cl were inhibited more strongly than by 2F8 mAb by
unlabelled AcLDL, by ~28 and 43%, respectively (Fig 7H) and the use of AcLDL seems to en-
able accurate estimation of SR-A contribution to the uptake of proteins by BM-DC as AcLDL
decreased their uptake to the level seen in SR-A-/- BM-DC and had no effect on the uptake by
SR-A-/- cells (S4C Fig, left panel).
For examining roles of CD36 and SR-A in the presentation of HOCl-modified proteins to
specific Th lymphocytes by live APC the available blocking agents could not be used because,
as we showed previously [18,31], they exhibit agonistic properties upon binding to receptors
and trigger intracellular signalling which affects APC functions of macrophages and DC. We
therefore took advantage of the availability of receptor-deficient mice. In comparison to WT
controls, in SRA-/- BM-DC uptake of AF-OVA-Cl was decreased by ~27% (Fig 3A, left panel).
SR-A-deficiency had an even stronger effect on the internalisation of HOCl-modified proteins
into acidic endosomes: relative to WT cells, in SR-A-/- cells endocytosis of pHr-OVA-Cl was
decreased by ~48% and that of pHr-HSA-Cl by as much as ~65% (Fig 3A, right panel). As
might be expected, in SR-A deficient BM-DC uptake of AcLDL was very strongly decreased
(~80%). BM-DC exhibited minimal endocytosis of pHrodo-labelled native HSA, ~12-times
lower than that of the same concentration of pHr-HSA-Cl, which was not significantly affected
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by SR-A deficiency (Fig 3A, right panel). The lack of SR-A in BM-DC had a delayed effect on
the presentation of OVA-Cl by these cells, as assessed by IL-2 production in the co-culture
with OT-II CD4+ lymphocytes: ~28% decrease of IL-2 production relative to the co-culture
with WT BM-DC was observed in the 2nd, but not in the 1st day of co-culture (Fig 3C). The rel-
atively mild effect of SR-A deficiency on the presentation of OVA-Cl does not seem to be
caused by compensatory up-regulation of alternative endocytic receptors, as SR-A-/- BM-DC
expressed unaltered levels of MR and SREC-I, whereas expression of CD36 was actually de-
creased by ~31% on SR-A-/- BM-DC relative to WT BM-DC (Fig 3B).
In CD36-deficient BM-DC uptake of AcLDL was decreased by ~18%, but CD36 deficiency
had no significant effect on the uptake of any other ligand tested (Fig 3A). Also, CD36-defi-
cient BM-DC presented OVA and OVA-Cl as effectively as WT cells (Fig 3C). Together with
the above shown ineffectiveness of blocking mAb (S4A Fig), these results indicate that CD36
does not have an evident contribution to either uptake or presentation of HOCl-modified pro-
teins by BM-DC, which may be caused by the fact that only a minority of BM-DC express this
receptor at low level. Therefore, in order to verify the ability of CD36 to mediate uptake and
presentation of HOCl-oxidised proteins we examined PEM, another type of APC which, as
shown in Fig 7E, express CD36 at very high level. Relative to WT PEM, in CD36-/- PEM up-
take of AF-OVA-Cl was decreased by ~17% and internalisation of pHr-OVA-Cl by ~27%
(Fig 3D). In contrast, CD36-deficiency had no significant effect on the uptake of AF-OVA or
pHr-HSA-Cl (Fig 3D).
Relative to WT PEM, CD36-/- PEM expressed as much as ~2-times more SR-A on their sur-
faces (Fig 3E). However, a relatively mild effect of CD36 deficiency on the uptake of OVA-Cl
does seem to result from the compensation by enhanced SR-A-mediated uptake because in
SR-A-deficient PEM AcLDL or oxLDL had similar effects on AF-OVA-Cl or pHr-OVA-Cl up-
take (S4C Fig,middle and right panels) as CD36 deficiency (Fig 3D). SR-A was responsible for
~35% of the total uptake of AF-OVA-Cl and ~40% of pHr-OVA-Cl internalisation, as indicat-
ed by both effects of SR-A deficiency (Fig 3D) and of AcLDL on these ligands uptake by
CD36-/- PEM (S4C Fig,middle and right panels). SR-A-deficient PEM also exhibited very
strong impairment of AF-OVA (~42%) and pHr-HSA-Cl (~46%) uptake (Fig 3D).
Despite SR-A contributing more to the uptake of OVA-Cl than CD36, CD36-deficient, but
not SR-A-deficient PEM exhibited significantly impaired presentation of OVA-Cl: ~39 and
32% decrease of IL-2 production in the co-culture with CD36-/- PEM was observed in the 1st
and the 2nd day, respectively (Fig 3F). Our results also confirm superior APC function of DC
over macrophages. OVA-Cl-pulsed BM-DC stimulated ~4.4–7.2-times higher IL-2 production
in OT-II lymphocytes than PEM and native OVA stimulated significant IL-2 production only
in the co-culture with BM-DC (compare Fig 3C and 3F). Moreover, antigen presentation by
PEM was more transient than by BM-DC, as indicated by decreased IL-2 levels in the 2nd day
when PEM, but not BM-DC were used as APC. However, stimulation with LPS improved pre-
sentation of OVA-Cl by PEM (~10.2-fold in the 1st day), more strongly than by BM-DC
(~4.3-fold) (Fig 3G). Moreover, whereas LPS abolished the effect of SR-A deficiency on the pre-
sentation of OVA-Cl by BM-DC, in PEM it potentiated the effect of SR-A deficiency, which be-
came significant (~41%).
We also assessed effects of CD36 or SR-A deficiencies on the presentation of HOCl-oxidised
proteins in vivo (Fig 3H). In comparison to WT controls, titers of antigen-specific IgM were on
average ~2.3-times higher in sera of SR-A-/- mice immunized 8 days earlier with 20 μg
OVA-Cl, but not with 20 μg HSA-Cl. In contrast, in CD36-/- mice primary humoral responses
to HSA-Cl, but not to OVA-Cl, were significantly impaired, as indicated by ~2.5-times lower ti-
ters of HSA-specific IgM.
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SR LOX-1 and SREC-I as well as RAGE are able to bind chlorinated
proteins, but do not contribute to OVA-Cl uptake by BM-DC
The role of LOX-1 as a receptor for HOCl-modified proteins has been suggested by a recent re-
port demonstrating increased uptake of fluorescein-labelled OVA-Cl by CHO cells upon trans-
fection with LOX-1 [12]. As shown in Fig 8A, rLOX-1 bound strongly to GA-BSA, used as a
positive control, and only slightly less strongly to TFN-Cl. In comparison, the binding to
OVA-Cl was weak, even weaker to OVA and no specific binding of rLOX-1 to BSA or TFN
was observed. Binding of rLOX-1 to OVA-Cl was almost completely blocked by DS already at
10 μg/ml (Fig 8B). In contrast, CS and mannan had no effect on rLOX-1 binding to OVA-Cl,
indicating that rLOX-1 preserves the ligand binding specificity of natural LOX-1. Results of ad-
ditional competition experiments have confirmed low affinity of OVA and OVA-Cl for rLOX-
1; whereas TFN-Cl dose-dependently inhibited rLOX-1 binding to GA-BSA, no inhibition was
produced by OVA or OVA-Cl even at 0.1 mg/ml (Fig 8C). HOCl-modified lipoproteins,
shown to bind to human LOX-1, were oxidised with higher concentrations of HOCl [32] than
our OVA-Cl preparation. We therefore prepared a more heavily HOCl-oxidised OVA-Cl by
incubating OVA with 6 mM instead of 3 mM NaOCl (OVA-ClH), and assessed its binding to
Fig 8. LOX-1 is capable of binding HOCl-modified proteins, but does not contribute to OVA-Cl uptake by BM-DC. (A) Binding of rLOX-1 to plate-
adsorbed proteins. (B, C) Effects of 10 or 100 μg/ml of indicated, soluble ligands on rLOX-1 binding to plate-adsorbed OVA-Cl (B) or GA-BSA (C). (D) Binding
of PE-conjugated anti-mouse LOX-1 mAb and control rat IgG2a to CBA BM-DC, determined by flow cytometry. (E) The effect of blocking goat anti-mouse
LOX-1 polyclonal Ab, relative to normal goat IgG, on AF-OVA-Cl uptake by untreated and LPS-pre-treated CBA BM-DC. (F) LOX-1 expression on LPS-pre-
treated CBA BM-DC. Results of single experiments are shown, repeated at least twice with similar results. The data were analysed by the Student’s t-test (A,
E) or by ANOVA, followed by the Tukey-Kramer post-test (B, C). *, p< 0.05; NS, non-significant.
doi:10.1371/journal.pone.0123293.g008
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rLOX-1. OVA-ClH turned out to be a higher affinity ligand of LOX-1 than OVA-Cl, inhibiting
rLOX-1 binding with a similar potency as DS (Fig 8C). We then assessed involvement of LOX-
1 in OVA-Cl uptake by BM-DC. LOX-1 was expressed on ~10–13% BM-DC generated from
C57BL/6 or CBA mice (Fig 8D). LOX-1-positive BM-DC were among cells exhibiting the high-
est level of AF-OVA-Cl uptake (S6A Fig). However, blocking anti-LOX-1 Ab had no effect on
AF-OVA-Cl uptake by BM-DC of either strain (Fig 8E). As the apparent lack of LOX-1 in-
volvement in OVA-Cl uptake by untreated BM-DC might be caused by the lack of LOX-1 ex-
pression on the majority of cells, we up-regulated LOX-1 expression on BM-DC by pre-
incubation with LPS. The LPS pre-treatment increased the average expression level of LOX-1
by as much as 3.4–4.3-fold, and the percentage of LOX-1-expressing BM-DC to ~39%, in case
of C57BL/6 cells (S6B Fig), and to ~60%, in case of CBA cells (Fig 8F). However, also in LPS-
pre-treated CBA BM-DC blocking anti-LOX-1 Ab had no effect on AF-OVA-Cl uptake (Fig
8E). Collectively, these results indicate that LOX-1 does not function as a receptor for OVA-Cl.
Other receptors implicated in the binding of covalently-modified proteins include: SR
SREC-I and FEEL-1/stabilin-1 as well as RAGE. From among these receptors, only RAGE was
tested for the ability to bind HOCl-oxidised proteins and suggested to be a high-affinity recep-
tor for HOCl-oxidised LDL and BSA, although, in our opinion, the claim concerning affinity of
the observed binding was not substantiated [33,34]. When ligands were coated at 20 μg/ml,
rSREC-I at 1 μg/ml bound strongly to adsorbed AcLDL and GA-BSA, used as positive controls,
but no specific binding to HOCl-modified proteins was observed, except of very weak binding
to TFN-Cl (S7A Fig). However, under conditions of increased concentrations of both coated
proteins (40 μg/ml) and rSREC-I (1.5 μg/ml), a significant specific binding of rSREC-I to
HOCl-modified proteins as well as OVA, but not to TFN or HSA, could be observed (Fig 9A).
Low affinity of HOCl-modified proteins for rSREC-I has been confirmed in competition exper-
iments. TFN-Cl and OVA-Cl produced weak, ~14% inhibition of rSREC-I binding to AcLDL
only at the higher concentration of 0.1 mg/ml (Fig 9B). In contrast, rSREC-I binding was inhib-
ited strongly and dose-dependently by DS and, less potently, by GA-BSA, but not by CS.
BM-DC exhibited uniform, low expression of SREC-I (Figs 3B and 9C). Two roughly equal-
ly numerous populations of PEM differing in size, as indicated by forward scatter, also differed
in SREC-I expression. SREC-I was expressed at moderate level on the majority of smaller cells
exhibiting high binding of control goat IgG, whereas it was expressed on only ~30% of larger
cells to which control goat IgG bound very weakly (S7B Fig). It has been reported that LPS in-
creases SREC-I expression on PEM and, consequently, contribution of SREC-I to AcLDL up-
take by these cells [35]. Pre-treatment with LPS increased the cell surface expression of SREC-I
on BM-DC ~1.6-fold (Fig 9C). Polyclonal goat Ab, generated against the extracellular portion
of mouse SREC-I, inhibited AcLDL uptake by LPS-pre-treated BM-DC by 8–11%, but had no
effect in untreated cells (S7C Fig). It has been also reported that SR-A masks the involvement
of SREC-I in AcLDL uptake [35]. Consistently, in LPS pre-treated, SR-A-deficient BM-DC
anti-SREC-I Ab exhibited increased potency, inhibiting AcLDL uptake by ~36% (Fig 9D). In
contrast, the Ab had no effect on AF-OVA-Cl or pHr-HSA-Cl uptake by LPS-pre-treated WT
or SR-A-/- BM-DC, indicating that SREC-I does not play a role in the uptake of HOCl-modi-
fied proteins by BM-DC. These results corroborate the conclusion drawn from experiments
with rSREC-I that HOCl-modified proteins are not high affinity ligands of SREC-I.
In comparison to binding to GA-BSA, used as a positive control, binding of rRAGE to
TFN-Cl and OVA-ClH was weak, and even weaker to OVA-Cl and HSA-Cl (Fig 9E). The same
rank of relative ligand affinities for rRAGE was indicated by results of competition experi-
ments. Only the higher, 0.1 mg/ml concentrations of TFN-Cl and OVA-ClH inhibited rRAGE
binding to GA-BSA, by ~21% and ~36%, respectively, whereas OVA-Cl was not inhibitory
even at this high concentration (Fig 9F). In contrast, the rRAGE binding was inhibited strongly
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by DS, GA-BSA and, unlike in the case of SR, also by CS (Fig 9F). Moreover, RAGE was ex-
pressed on the surface of neither BM-DC nor PEM, as indicated by the absence of specific
binding of three different anti-RAGE Ab: rat anti-mouse RAGE mAb (clone 175440, R&D Sys-
tems) and two different goat anti-mouse RAGE polyclonal Ab (from R&D Systems and Santa
Cruz Biotechnology) (S7D Fig). The absence of RAGE expression on BM-DC has been re-
ported previously [30]. The lack of specific binding of two different anti-stabilin-1 Ab: goat
anti-mouse stabilin-1 and rabbit anti-mouse stabilin-1 polyclonal Ab indicates that also stabi-
lin-1 is not expressed on the surface of BM-DC (S7E Fig).
The mannose receptor (CD206) is responsible for the component of
chlorinated proteins uptake which is inhibited by both mannan and DS
The above results indicate that SR-A and CD36 are the receptors responsible for the portion of
chlorinated proteins uptake which is inhibited by DS, but not by mannan. The best candidate
for the receptor mediating the fraction of HOCl-modified proteins uptake which is inhibited
by both DS and mannan was the mannose receptor (MR/CD206). First, MR was expressed on
BM-DC (Fig 10A). A small parallel shift of the histogram representing cells labelled with anti-
MR mAb relative to that depicting cells incubated with an isotype control, indicates that the
Fig 9. Both SREC-I and RAGE bind HOCl-oxidised proteins with low affinities. (A) Binding of rSREC-I to proteins coated onto ELISA plates. (B) Effects
of 10 or 100 μg/ml of indicated, soluble ligands on rSREC-I binding to plate-adsorbed AcLDL. (C) Binding of goat anti-mouse SREC-I Ab to untreated and
LPS-pre-treated BM-DC. (D) Effects of polyclonal goat anti-mouse SREC-I Ab, relative to normal goat IgG, on the uptake of AF-AcLDL, AF-OVA-Cl and pHr-
HSA-Cl by LPS-pre-treated, SR-A-deficient BM-DC. (E) Binding of rRAGE to plate-adsorbed proteins. (F) Effects of 10 or 100 μg/ml of indicated, soluble
ligands on rRAGE binding to plate-adsorbed GA-BSA. The data were analysed by the Student’s t-test (A, D, E) or by ANOVA, followed by the Tukey-Kramer
post-test (B, F). *, p< 0.05; NS, non-significant.
doi:10.1371/journal.pone.0123293.g009
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majority of BM-DC express MR at low level. Splenic DC expressed ~2-times more MR than
BM-DC, whereas the expression level of MR on PEM was intermediate (Fig 10A). Second,
OVA is a well-established ligand of MR [36], whereas the occurrence of mutual cross-competi-
tion indicates that OVA-Cl binds to the same receptors on BM-DC as OVA (Fig 5A). Third, in
J774 macrophage-like cells, which express several endocytic receptors at high level, including
Fig 10. The role of MR as a receptor for HOCl-modified proteins. (A) Geometric mean fluorescence intensity of anti-MRmAb and isotype-matched
control rat IgG2a binding to BM-DC, splenic DC and PEM. The graph on the right shows a representative histogram for BM-DC. (B) Effects of mannan (Man),
DS and CS on AF-OVA-Cl uptake by J774 cells. (C) Binding of rMR to plate-adsorbed proteins. (D) Effects of 10 or 100 μg/ml of indicated, soluble ligands on
rMR binding to plate-adsorbed TFN-Cl. (E) Effects of agents selectively blocking C-type lectin domains (EDTA, anti-MRmAb) or the cysteine-rich domain
(CS) on rMR binding to plate-adsorbed OVA or OVA-Cl. (F) Uptake of indicated, fluorescently-labelled ligands byWT and MR-/- BM-DC. (G, H) IL-2
production in the co-culture of CD4+ OT-II lymphocytes with WT or MR-/- BM-DC pulsed for 3.5 h with 20 μg/ml OVA, 7 μg/ml OVA-Cl (G) or OVA-Cl + 200 ng/
ml LPS (H). The results shown are averages +SEM from 4 independent experiments (A, F-H) or mean values +SEM obtained in single experiments, repeated
2–3 times with similar results (B-E). The data were analysed by the Student’s t-test (C, F-H) or by ANOVA, followed by the Tukey-Kramer post-test (B, D, E).
*, p< 0.05;!, a statistically significant additive effect of two ligands; NS, non-significant.
doi:10.1371/journal.pone.0123293.g010
HOCl Increases Immunogenicity of Proteins
PLOS ONE | DOI:10.1371/journal.pone.0123293 April 7, 2015 25 / 39
SR-A [37] and CD36 [17], but do not express MR [38], mannan had no effect on OVA-Cl up-
take (Fig 10B). Finally, although mannan is also a ligand of other receptors, MR is the only
known receptor that in addition to mannan also binds sulphated saccharides [26].
The ability of MR to bind HOCl-modified proteins has been confirmed in experiments with
rMR. rMR bound weakly to adsorbed OVA, used as a positive control (Fig 10C). The binding
of rMR to OVA-Cl was as much as ~6-times higher than that to OVA. rMR exhibited similarly
high binding to TFN-Cl and HSA-Cl, but no specific binding to HSA and TFN could be de-
tected (Fig 10C). To further characterize binding specificity of rMR, we performed competition
experiments. Among non-proteinaceous ligands, DS turned out to be the most potent competi-
tor, essentially blocking binding of rMR to TFN-Cl already at 10 μg/ml, followed by CS and
mannan (Fig 10D); mannan and CS inhibited binding of rMR to adsorbed OVA-Cl with IC50
values of ~184 and 9.9 μg/ml, respectively (S8A Fig). Whereas OVA-Cl inhibited binding of
rMR to TFN-Cl almost as potently as DS, OVA had no effect even at 0.1 mg/ml, confirming
that OVA is a low-affinity ligand of MR. However, the affinity of OVA, as well as of other pro-
teins, to MR is dramatically increased by HOCl-mediated oxidation. Paradoxically, DS at
100 μg/ml increased binding of rMR to TFN-Cl (Fig 10D and S8B Fig). At these high concen-
trations (>10 μg/ml) DS seems to enhance non-specific binding of rMR as it also produced
strongly increased binding of rMR to non-coated (blocked only) wells. In contrast, at 10 μg/ml
DS selectively inhibited rMR binding to wells coated with TFN-Cl or OVA-Cl, but had no ef-
fect on non-specific attachment to uncoated wells (S8C Fig).
Three different types of domains have been implicated in ligands binding to MR: eight C-
type lectin domains (CTLD) bind in a calcium-dependent manner oligosaccharides terminat-
ing with mannose, fucose or N-acetylglucosamine (with the most prominent role played by
CTLD4), the single fibronectin type II repeat is responsible for binding to collagens and the N-
terminal cysteine-rich domain (CysR) mediates the receptor binding to sulphated saccharides
[26,36,39–42]. In order to gain insight into the role of these domains in MR binding to
OVA-Cl, we used domain-selective agents in competition experiments: a divalent cations che-
lator EDTA or mAb generated against CTLD4-7 to inhibit CTLD and CS to selectively block
CysR of MR [26]. Both EDTA and anti-CTLD mAb produced stronger inhibition of rMR bind-
ing to OVA (by ~76 and 40%, respectively) than to OVA-Cl (54 and 9%) (Fig 10E), indicating
that CTLD play a relatively more important role in MR binding to OVA than to OVA-Cl. Sur-
prisingly, CS inhibited rMR binding to both OVA and OVA-Cl (40 and 46%). However, CS
and anti-CTLD mAb had an additive effect on rMR binding to OVA, but not to OVA-Cl, and
the combination of CS and EDTA produced complete inhibition of rMR binding to OVA, but
only partial, 77% inhibition of the receptor binding to OVA-Cl (Fig 10E). Thus, both CTLD
and CysR seem to contribute to OVA and OVA-Cl binding to MR. These two domains account
entirely for rMR binding to OVA, whereas in the case of OVA-Cl other parts of MR molecules
may be also involved. The complete inhibition of rMR binding to TFN-Cl by DS (Fig 10D) in-
dicates that DS blocks both CTLD and CysR.
The role of MR in the uptake and presentation of HOCl-oxidised proteins has also been as-
sessed in experiments employing BM-DC generated fromMR-deficient mice. In comparison
to WT controls, in MR-/- BM-DC uptake of AF-OVA-Cl was decreased by ~36% and that of
AF-OVA by as much as ~85% (Fig 10F). Effects of MR deficiency indicate that, inversely to SR,
MR had a relatively larger contribution to the total uptake of OVA-Cl than to the internalisa-
tion of this ligand into acidic endosomes, as in MR-/- BM-DC internalisation of pHr-OVA-Cl
was reduced by ~21% only. Internalisation of pHr-HSA and pHr-HSA-Cl was not affected sig-
nificantly by MR deficiency.
In MR-/- BM-DC presentation of OVA-Cl was decreased to a similar extent as the uptake of
AF-OVA-Cl, by ~31 and 41%, respectively, in the 1st and the 2nd day of co-culture (Fig 10G). In
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contrast, despite the fact that in MR-/- BM-DC uptake of OVA was drastically decreased
(Fig 10F), MR-deficient BM-DC did not exhibit significant impairment of OVA presentation
(Fig 10G). In MR-/- BM-DC, also the presentation of OVA-Cl in the presence of LPS was de-
creased, by ~51% (Fig 10H).
LPS and SR-A ligands modulate intracellular routing and proteolytic
processing of endocytosed proteins
In addition to the up-regulation of co-stimulatory molecules expression and induction of cyto-
kine production in APC, the adjuvant effect of TLR agonists has also been suggested to involve
stimulation of antigen processing [43]. The overnight pre-treatment with LPS strongly inhib-
ited, by ~59%, uptake of AF-OVA-Cl by BM-DC (Fig 11A). In LPS-pre-treated BM-DC acidifi-
cation of internalised pHr-OVA-Cl and degradation of DQ-OVA were less strongly decreased,
by ~51–52%, indicating that in LPS-pre-treated BM-DC strongly decreased uptake of antigens
is accompanied by their slightly (by ~20%) enhanced lysosomal degradation. In contrast, in
Fig 11. LPS and SR-A ligands regulate uptake, acidification and proteolysis of endocytosed antigens. (A) Effects of 1-day pre-treatment with 100 ng/
ml LPS on the total uptake of AF-OVA-Cl, internalisation of pHr-OVA-Cl and degradation of DQ-OVA by BM-DC and PEM. (B, C) Effects on indicated ligands
on the acidification of pHr-OVA-Cl-containing endosomes (B) and proteolytic digestion of DQ-OVA (C) in BM-DC and PEM. The results shown are averages
+SEM from 3 independent experiments, each performed in 4 replicates. The data were analysed by the Student’s t-test (A) or by ANOVA, with the Dunnett’s
post-test applied to compare the control (“medium”) with other groups (B, C). *, p< 0.05.
doi:10.1371/journal.pone.0123293.g011
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PEM pre-treatment with LPS did not affect the uptake level of AF-OVA-Cl, but decreased by
~23% both pHr-OVA-Cl delivery into acidic endosomes and proteolytic degradation of
DQ-OVA (Fig 11A).
We also assessed the effect of an “acute” treatment with LPS on the degradation of internal-
ised antigens. APC were incubated on ice with fluorescently-labelled OVA preparations. Subse-
quently, unbound antigens were washed out and the cells were transferred to 37°C for 2-h
incubation with or without LPS. In BM-DC the LPS treatment inhibited acidification of pHr-
OVA-Cl by ~25% (Fig 11B) and degradation of DQ-OVA by ~18% (Fig 11C). Although in
PEM LPS had a smaller percent effect on pHr-OVA-Cl delivery into acidic endosomes (~17%),
due to the fact that PEM internalised ~5.1-times more pHr-OVA-Cl than BM-DC, the absolute
value of inhibition was ~3.5-fold larger (Fig 11B). In contrast, LPS produced ~1.4-times stron-
ger, ~26% inhibition of DQ-OVA degradation in PEM than in BM-DC (Fig 11C). Taking into
account that in PEM degradation of DQ-OVA was ~3.3-times more intense, this means that in
PEM ~5-times more DQ-OVA was spared from degradation as the result of LPS treatment
than in BM-DC. Effects of LPS on DQ-OVA degradation were mimicked by ligands of SR-A,
but not by mannan. Inclusion of DS in the incubation medium inhibited delivery of pHr-
OVA-Cl into acidic compartments in both PEM (~25%) and BM-DC (~28%) (Fig 11B), where-
as proteolytic degradation of DQ-OVA was inhibited by DS in PEM only (~21%) (Fig 11C). In
contrast, cross-linking of SR-A with specific mAb inhibited degradation of DQ-OVA in both
PEM (by ~23%) and BM-DC (~31%) (Fig 11C), but had no effect on the acidification of pHr-
OVA-Cl-containing endosomes (Fig 11B).
Discussion
During primary immune response, endocytic receptors from SR and the C-type lectin families
play the main role in antigen uptake by APC. Paradoxically, these receptors do not bind the
majority of native proteins. For instance, the repertoire of proteins bound to MR is limited to
collagens and glycoproteins containing oligosaccharides terminated with mannose, fucose or
N-acetylglucosamine or modified with sulphuric acid [36,39–42,44], whereas SR-A binds with
high affinity to proteins which, owing to covalent modification, gain a net negative charge [45].
During repeated contact with the same antigen, the presence of specific Ab may enable uptake
of proteins through Fc receptors, and in case of Ab activating complement, also through com-
plement receptors on APC [46]. Moreover, DC and macrophages were demonstrated to be ca-
pable of taking over through SR-A protein antigens bound to BCR on B lymphocytes [47], but
also this mechanism is unlikely to play a significant role during primary response, when the
percentage of naive B lymphocytes expressing BCR specific for a given antigen is very low. In
case of intracellular proteins, their uptake by APC may be facilitated by association with heat
shock proteins (HSP). When released from necrotic cells, such complexes of HSP with peptides
may be endocytosed by APC through SR and efficiently presented [48].
None of the above listed mechanisms is likely to operate during the first encounter with ex-
ogenous protein antigens. In fact, insufficient uptake by APC may be the major limiting factor
responsible for the observed very poor immunogenicity of purified proteins. However, it is pos-
sible to boost immunogenicity of proteins by co-administration of adjuvants. A shared feature
of different types of adjuvants is their ability to trigger acute inflammation, characterized by
early influx of activated neutrophils, eosinophils and monocytes [6–8]. Acute inflammation is
also triggered by other factors disturbing tissue homeostasis, such as infection and sterile inju-
ry. Similarly, parasitic worms, by moving and feeding inside tissues cause damage, provoking
inflammatory responses. Chemoattractants, responsible for the influx of neutrophils, at higher
concentrations present in inflammatory foci, also stimulate respiratory burst in these cells,
HOCl Increases Immunogenicity of Proteins
PLOS ONE | DOI:10.1371/journal.pone.0123293 April 7, 2015 28 / 39
which may be further enhanced by pathogens or their products. We demonstrated herein that
the potent oxidant produced under these conditions—HOCl converts different proteins and
glycoproteins, which in their native forms do not bind or bind weakly to endocytic receptors,
into high-affinity ligands of these receptors. Endocytosed proteins are subsequently processed
and presented to Th lymphocytes. Importantly, HOCl-modified proteins alone, devoid of con-
tamination with PRR agonists, were able to elicit adaptive immune responses. These results in-
dicate that when the uptake of protein antigens is improved, resulting in the presentation of
sufficiently high density of complexes of epitopes with MHC-II on the surface of APC, other
factors, such as stimulation of PRR, are not necessary to induce these responses. This conclu-
sion is supported by previously reported observations that selective targeting of protein anti-
gens to either MR or CD36 on DC is sufficient to induce robust immune responses in vivo, in
the absence of any adjuvant [4,49]. Results of our experiments aimed at elucidation of mecha-
nisms of induction of immune responses under these conditions have revealed that the TCR-
mediated recognition of complexes of non-self oligopeptides with MHC-II by Th lymphocytes
alone seems sufficient to induce production of IL-2 in these cells. In turn, a reverse signalling
stimulated in BM-DC by engagement of MHC-II up-regulates expression of CD40 in these
cells. Subsequent interaction of CD40 on DC with CD40L on Th cells leads to up-regulation of
CD86 expression on DC, whereas in Th cells it provides co-stimulation for IFN-γ production.
It has been established that differentiation of IFN-γ-producing Th1 lymphocytes is favoured by
high density of MHC-II with peptides on the surface of APC [50], which may explain why
BM-DC pulsed with OVA-Cl stimulated much higher IL-2 and IFN-γ production than those
pulsed with OVA, despite similar production of IL-12p40. The density of epitopes displayed on
APC seems to be also the major factor regulating the Th1/Th2 polarisation of immune re-
sponses to HOCl-oxidized proteins in vivo, as in CBA mice humoral immune response to a
low dose (10 μg) of OVA-ClL was Th2-polarized, whereas that stimulated by a high dose
(100 μg) of the same antigen exhibited the Th1 polarisation. In contrast, confirming our previ-
ous report [18], neither OVA nor OVA-Cl stimulated production of IL-4 in the in vitro co-cul-
tures with OT-II CD4+ cells under any conditions. This strong bias of immune responses
toward the Th1 type in OT-II transgenic mice has also been recently reported by others [51].
We were surprised to find that the ability to bind HOCl-oxidised proteins was a shared fea-
ture of all non-homologous and structurally diverse receptors examined by us. However, uptake
and presentation of OVA-Cl by BM-DC were mediated by MR and SR-A, whereas in the case
of PEM CD36 was additionally involved. Other receptors capable of binding HOCl-oxidised
proteins were not involved in the uptake of OVA-Cl by BM-DC because they were either not
expressed (RAGE) or required stronger oxidation of OVA (LOX-1, RAGE). As antigenicity of
such heavily oxidised proteins is likely to be largely lost, the latter receptors might be involved
in the scavenging, but not in the presentation of oxidised proteins. The presence of such heavily
oxidised LDL, containing modifications occurring at HOCl:protein molar ratios higher than
100:1, has been detected in human atherosclerotic lesions [52]. It has been established that
amino acid side chains are major targets in HOCl-mediated oxidation of proteins, with the
order of reactivity being: Met> Cys>>His> Trp> Lys>> Tyr~Arg. As sulphur-containing
groups of Met and Cys react with HOCl with by far the fastest kinetics, they become selectively
oxidised at very low molar ratios of HOCl to accessible reactive groups in proteins, after which
ε-amino groups in Lys side chains react, resulting in the production of chloramines
[9,12,53,54]. Oxidation of Met and Lys residues, which are absent in the epitope recognized by
OT-II lymphocytes, but common in other OVA epitopes, may explain why the in vivo immu-
nogenicity of OVA-Cl is largely lost, whereas its presentation in the co-culture with OT-II lym-
phocytes continues to increase even further upon an additional oxidation by neutrophils.
Neutralization of the positive charge of ε-amino groups in Lys upon chlorination confers on
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proteins a net negative charge, being the shared feature of ligands of SR, RAGE and of CysR in
MR. Subsequent decomposition of Lys chloramines may lead to the generation of carbonyl
products, but in OVA-Cl only ~14% of Lys seemed to undergo such irreversible modifications,
as indicated by changes in degrees of labelling with amino-selective fluorescent dyes (thiosul-
phate, added before labelling, converts chloramines back to amines) and by direct quantifica-
tion of free carbonyl groups [12]. However, even such low level of modification turned out to be
sufficient to transform proteins into high-affinity ligands of CD36 and MR. Consistently, it has
been found that HOCl-mediated oxidation of only ~5% of Lys in LDL leads to enhanced recog-
nition by CD36 [29]. In contrast, LDL binding to SR-A requires modification of>16% of Lys,
although modification of as many as>60% of Lys was necessary to attain maximal binding
[29,55,56]. Nevertheless, despite the fact that proteins oxidised with 3 mMHOCl bound weekly
to SR-A (Fig 7G), their uptake by APC was strongly SR-A-dependent. This apparent discrepan-
cy may be explained by the relatively high expression of SR-A (BM-DC) or by SR-A being
much more efficient than CD36 in mediating endocytosis of bound ligands (PEM) [56]. Even
stronger oxidation was required to render OVA a ligand of RAGE. Whereas generation of SR li-
gands requires modification of specifically Lys side chains [55], conferring on a protein a strong,
net negative charge by itself seems to be sufficient to convert it into a RAGE ligand [57]. Unlike
OVA-Cl, TFN-Cl was a high affinity ligand of LOX-1, but we were unable to assess the ability
of LOX-1 to mediate presentation of TFN-Cl because of the presence of ubiquitous receptors
for native TFN. Consequently, immunization with native human TFN induced very high titer
of TFN-specific Ab in mouse sera, which was similar to that induced by TFN-Cl (S9 Fig). Im-
portantly, no detectable Ab production was induced by mouse TFN-Cl, which does not support
the suggested possibility [58] that chlorination is able to brake tolerance to self proteins.
Results of experiments with DQ-OVA and comparisons of effects of receptor deficiencies
on the internalisation of pHr-OVA-Cl into acidic endosomes versus the total uptake of AF-O-
VA-Cl indicate that proteins internalised through SR are subjected to stronger acidification
and more intense degradation than those endocytosed through MR. It has been already re-
ported that in BM-DC and macrophages MR and SR deliver internalised ligands into distinct
intracellular compartments [59]. In these cells OVA internalised through MR was directed into
stable, early endosomes, which resisted strong acidification for a prolong period, and in which
OVA-derived peptides were loaded onto MHC class I molecules for subsequent cross-presenta-
tion to CD8+ T lymphocytes. In contrast, in macrophages unidentified receptors inhibited by
polyinosinic acid, presumably SR, mediated internalisation of OVA into MHC-II-positive en-
dosomes, which underwent rapid acidification and fusion with lysosomes. Moreover, more in-
tense and complete degradation of endocytosed proteins inside macrophages than in DC may
be an important reason why macrophages underperformed as APC, despite endocytosing sev-
eral-fold higher amounts of proteins than BM-DC [60] (S5 Fig). Consequently, whereas in
BM-DC a portion of proteins endocytosed through SR-A seems subjected to partial degrada-
tion into oligopeptides suitable for loading onto MHC-II, in PEM proteins internalised through
the same receptor may undergo faster and more complete degradation, precluding their pre-
sentation. However, the excessive degradation of antigens in macrophageal endosomes may be
reduced upon activation with LPS and/or IFN-γ [61,62]. Accordingly, we have observed that
pre-treatment with LPS inhibits acidification of pHr-OVA-Cl-containing endosomes as well as
proteolysis of DQ-OVA in PEM, but not in BM-DC, and more strongly enhances presentation
of OVA-Cl-derived peptides by PEM than by BM-DC. Moreover, in macrophages LPS en-
hanced the effect of SR-A deficiency on the presentation of OVA-Cl, which may also be ex-
plained by inhibitory effects of LPS on the digestion of endocytosed antigens. Thanks to this
activity LPS may prevent complete proteolytic destruction of a portion of antigens internalised
through SR-A, enabling their presentation. Thus, adopting the function of professional APC by
HOCl Increases Immunogenicity of Proteins
PLOS ONE | DOI:10.1371/journal.pone.0123293 April 7, 2015 30 / 39
macrophages upon recognition of pathogen-associated molecular patterns through their PRR
seems to include sparing from total proteolysis and presentation of a larger portion of endocy-
tosed antigens. Interestingly, the effect of LPS on antigen degradation was reproduced by SR-A
cross-linking with mAb, likely mimicking SR-A engagement during phagocytosis mediated by
this receptor.
Conversely, LPS abolished the effect of SR-A deficiency on the presentation of OVA-Cl by
BM-DC. The most likely explanation of this observation is the enhancement of signal transduc-
tion from TLR occurring in SR-A-deficient DC. In SR-A-deficient DC [63,64], but not in SR-A-
deficient macrophages [18,65], LPS have been reported to stimulate much higher production of
pro-inflammatory cytokines than inWT cells as well as upon stimulation with TLR agonists
SR-A-/- DC [66], but not SR-A-/- PEM [18], exhibited strongly increased potency in priming
adaptive immune responses. Results of Yu et al. [64] indicate that in WT DC intracellular SR-A
inhibits TLR4 signalling as the result of binding to TNF receptor-associated factor 6 (TRAF6)
and sequestering it in late endosomes/lysosomes. Importantly, SR-A-/- BM-DC also exhibited
enhanced T cell stimulatory activity during presentation of protein antigens alone, in the ab-
sence of PRR agonists [66]. The mechanism of this effect is unclear, but it may include potentia-
tion of CD40 signalling, which also depends on TRAF6 [67]. Thus, the effects of SR-A
deficiency on antigen presentation in vitro and on humoral immune responses in vivo observed
in our study may be resultant of two opposite processes: decreased density of peptide-MHC-II
complexes on the surface of APC caused by decreased uptake and the relief from immunosup-
pression exerted in WT DC by intracellular SR-A. The net effect of these opposing factors may
be determined by the degree of SR-A-dependency of a given antigen uptake by DC.
Three factors: the use of vertebrate proteins which bind to endocytic receptors on APC also
in their native forms, strong enhancement of immune responses occurring in MPO-/- mice,
and co-uptake of proteins together with phagocytosed zymosan by APC seemed to be the main
reasons of the initial failure of our attempts to demonstrate the role of MPO-mediated protein
oxidation in vivo. Accordingly, the microbial protein YAD was not endocytosed by APC in its
native form and soluble inducers of acute inflammation significantly enhanced Ab production
in response to immunization with YAD inWT, but not MPO-/- mice, confirming in vivo role
of proteins oxidation by neutrophils’MPO in increasing their immunogenicity.
Although increased immunogenicity of HOCl-modified proteins apparently results mainly
from enhanced uptake by APC, this does not seem to be the sole mechanism. Prokopowicz
et al demonstrated that chlorination strongly increases susceptibility of OVA to digestion by
proteases [12]. The strong resistance of native OVA to digestion demonstrated in that study
may explain our observation that despite endocytosing ~7-times less OVA, MR-/- BM-DC pre-
sented it to CD4+ T lymphocytes as effectively as WT cells. Similar results were reported previ-
ously by Burgdorf et al. [59]. Apparently, in a weakly-digestive microenvironment of early
endosomes, to which ligands internalised through MR are targeted, native OVA is not pro-
cessed for presentation by MHC-II. However, this weakly acidic microenvironment of early en-
dosomes seems to provide favourable conditions for partial digestion of HOCl-oxidized OVA
into fragments suitable for loading onto MHC-II, as in MR-deficient BM-DC presentation of
OVA-Cl was decreased to the same extent (31–41%) as the total uptake of AF-OVA-Cl (36%).
In the case of BM-DC, also a portion of OVA-Cl internalised through SR-A appears to be pre-
sented, whereas in PEM faster and more intense degradation of OVA-Cl internalised through
the same receptor seems to largely preclude its presentation. In contrast, in the latter cell type,
internalisation through CD36 seems to provide close to optimal conditions for antigen presen-
tation as CD36 deficiency in PEM had much stronger effect on the presentation of OVA-Cl
(32–39%) than on the total uptake of AF-OVA-Cl (17%). Consistent with the specialization of
CD36 in the presentation of endocytosed antigens, despite high redundancy of receptors for
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HOCl-oxidized proteins, in CD36-/- mice immunization with HSA-Cl induced significantly
lower production of HSA-specific IgM than in WT controls.
In summary, our results have revealed a mechanism of recognition of non-self proteins
which is accomplished by co-operation between innate and adaptive immunity. We postulate
that this mechanism may enable the immune system to detect infections caused by parasitic
worms and possibly also by protozoan parasites, which, as being biochemically very similar, do
not synthesize kinds of compounds absent in mammalian hosts, and therefore cannot be de-
tected by innate immune cells through their PRR [68,69]. Main biochemical differences be-
tween mammalian hosts and these parasites seem to occur in amino acid sequences of
proteins, but proteins of all eukaryotic organisms are built from the same set of amino acids,
and as such are not good candidates for PRR ligands. However, in the detection of differences
in amino acid sequences of proteins lymphocytes, the major cell type of adoptive immunity,
are specialized, thanks to being furnished with recombined immunoglobulin receptors. Conse-
quently, one may speculate that infections caused by protozoan and metazoan parasites might
be an important part of selection pressure responsible for the evolving of adaptive immunity in
jawed vertebrates. The first step in our proposed mechanism of recognition of non-self proteins
is induction of acute inflammation, being a non-specific response triggered by essentially any
disturbance of tissue homeostasis (Fig 12). One of the major goals of acute inflammation seems
to be the recruitment of professional phagocytes. According to the model proposed, HOCl pro-
duced by these phagocytes would cause non-selective oxidation of both self and, if present,
pathogen-derived proteins, subsequently endocytosed by APC through several endocytic re-
ceptors and presented on their surfaces as complexes with MHCmolecules. In case of sterile in-
jury, presentation of self proteins only by APC would not induce adaptive immune responses,
whereas endocytic receptors, by scavenging apoptotic cells and tissue debris and by regulating
production of growth factors and cytokines, would promote resolution of inflammation, im-
munosuppression and tissue repair [70,71]. In contrast, strongly increased affinity of non-self
proteins to endocytic receptors, resulting from their HOCl-mediated oxidation, would allow
the immune system to detect their even very small amounts. In the absence of PRR ligands, the
major factor determining the type (polarisation) of adoptive immune response may be the dose
of antigens. Presentation of high density of complexes of MHC-II with non-self peptides by
APC, which either phagocytosed or became infected with intracellular protozoa, would result
in the induction of Th1-polarised immune responses, characteristic of infections caused by this
type of pathogens [72,73]. In turn, the presentation of only low density of MHC-II-peptide
complexes would favour the Th2/Treg polarisation of adoptive immunity during infections
with parasitic worms. The Th2/Treg polarisation under these conditions might be reinforced
by intracellular signalling triggered upon ligation of endocytic receptors, leading to suppression
of IL-12 and IL-6 and stimulation of IL-10 production and therefore creating a cytokine milieu
favouring differentiation of Th2/Treg over Th1/Th17 lymphocytes. This possibility is consis-
tent with the observed in this study inability of LPS to reverse the Th2 polarisation of immune
responses to HOCl-oxidised proteins and supported by results of our previous studies on sig-
nalling abilities of endocytic receptors. We have demonstrated that upon ligation with specific
Ab, DS or AcLDL SR-A mediates inhibition of LPS-stimulated IL-6 and IL-12, but enhance-
ment of IL-10 production [18,31], whereas ligation of CD36 with Ab was sufficient alone to in-
duce very high production of IL-10, capable of inhibiting IL-6 and IL-12 production in PEM
[18]. Others reported that also MR mediates inhibition of IL-12 and enhancement of IL-10 re-
lease [74,75]. In this context, our observation that, unlike in the case of OVA-Cl, increasing the
dose of HSA-Cl failed to produce the Th1-polarization of humoral response might be ex-
plained by binding of HSA-Cl to SR-A with a higher affinity than of OVA-Cl (Figs 3A and 7G)
[18]. Thus, HOCl-oxidised proteins may share the mechanism of the Th2-polarising effect
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with products (proteins and glycoproteins) excreted/secreted by parasitic worms, which were
found to be ligands of the same endocytic receptors as HOCl-modified proteins, including MR
[76–78] and SR-A [79]. Acting on APC these products inhibit IL-12 and enhance IL-10 pro-
duction and, consequently, induce strongly Th2-polarised immune responses in vivo [76–79].
Improved immunogenicity of HOCl-modified proteins might be exploited in the develop-
ment of more effective vaccines that, possibly, would not require co-administration of adju-
vants. Currently, the research on the potential application of HOCl-oxidised proteins in anti-
cancer vaccines is the most intensively pursued area and promising immunological and clinical
results have been already reported [80,81].
Fig 12. The proposedmechanism of the immunoenhancing effect caused by HOCl-mediated
oxidation of protein antigens. Administration of adjuvants, infection or sterile injury trigger acute
inflammation, characterized by recruitment and activation of neutrophils. Activated neutrophils produce HOCl
which causes non-selective oxidation of both self and, if present, pathogen-derived proteins, subsequently
endocytosed by DC through MR and SR-A, processed and presented as complexes with MHC-II on their
surface. TCR-mediated cognate interactions of Th lymphocytes with peptide-MHC-II complexes on DC
induce IL-2 production in Th lymphocytes (not shown) and up-regulate expression of CD40 on DC and of
CD40L on lymphocytes. Upon ligation with CD40L, CD40 induces expression of CD86, a ligand for CD28 on
Th lymphocytes. In the absence of PRR ligands, presentation of low density of peptide-MHC-II complexes on
DC stimulates differentiation of naive Th lymphocytes towards Th2 cells. The Th2 polarization is reinforced by
intracellular signalling triggered upon binding of HOCl-oxidised proteins to SR-A or MR, leading to the
suppression of IL-12 and enhancement of IL-10 production by DC.
doi:10.1371/journal.pone.0123293.g012
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Supporting Information
S1 Fig. One-day treatment with LPS, but not with OVA or OVA-Cl induces maturation of
BM-DC, as indicated by up-regulated expression of MHC-II and CD40 molecules (A) and
cytokine production (B).
(TIF)
S2 Fig. S. aureus- or zymosan-stimulated, lucigenin-enchanced chemiluminescence in WT
and MPO-/- neutrophils.
(TIF)
S3 Fig. Titers of antigen-specific antibodies in sera of WT and MPO-/- mice immunized
with: (A) HSA and zymosan depleted with TLR2 agonists or (B) OVA and heat-killed S. au-
reus or Pam3CSK4 lipopeptide.
(TIF)
S4 Fig. Roles of CD36 and SR-A as receptors for HOCl-oxidised proteins. (A, B) Effects of
anti-CD36 CRF D-2712 mAb (A) and anti-SR-A 2F8 mAb (B) on AF-AcLDL, AF-OVA or
AF-OVA-Cl uptake by BM-DC. (C) Effects of AcLDL or oxLDL on AF-OVA-Cl or pHr-
OVA-Cl uptake by BM-DC or PEM isolated fromWT, SR-A-/- and CD36-/- mice.
(TIF)
S5 Fig. Comparison of fluorescently-labelled ligands uptake by BM-DC vs. PEM
(TIF)
S6 Fig. The role of LOX-1 as a receptor for HOCl-oxidised proteins. (A) A relationship be-
tween the magnitude of AF-OVA-Cl uptake and LOX-1 expression on BM-DC. (B) LOX-1 ex-
pression on LPS-pre-treated C57Bl/6 BM-DC.
(TIF)
S7 Fig. Roles of SREC-I, RAGE and stabilin-1 as receptors for HOCl-oxidised proteins. (A)
Binding of rSREC-I to proteins adsorbed to ELISA plates. (B) Expression of SREC-I on PEM.
(C) Effects of anti-SREC-I Ab on AF-AcLDL uptake by BM-DC. (D) Binding of anti-RAGE
Ab to BM-DC. (E) Binding of anti-stabilin-1 Ab to BM-DC.
(TIF)
S8 Fig. The role of MR as a receptor for HOCl-oxidised proteins. (A, B) Dose dependent ef-
fects of mannan, CS (A) and DS (B) on rMR binding to plate-adsorbed OVA-Cl (A) or TFN-Cl
(B). (C) Effects of 10 μg/ml or 100 μg/ml DS on rMR binding to wells coated with TFN-Cl vs.
uncoated wells.
(TIF)
S9 Fig. Titers of specific IgG in sera of intact mice or mice immunized with mouse TFN-Cl,
human TFN or human TFN-Cl. C57BL/6 mice were injected i.p. twice with a 14-days interval
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